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Sísifo 
 
“Recomeça… 
Se puderes, 
Sem angústia e sem pressa. 
E os passos que deres, 
Nesse caminho duro 
Do futuro, 
Dá-os em liberdade. 
Enquanto não alcances 
Não descanses. 
De nenhum fruto queiras só metade. 
 
E, nunca saciado, 
Vai colhendo 
Ilusões sucessivas no pomar 
E vendo 
Acordado, 
O logro da aventura. 
És homem, não te esqueças! 
Só é tua a loucura 
Onde, com lucidez, te reconheças.” 
 
Miguel Torga, Diário XII 
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Resumo 
As infecções e formação de trombos são dois graves problemas associados à utilização de 
cateteres intravasculares em terapias de longa duração [1]. As estratégias que têm sido 
utilizadas, particularmente o revestimento de cateteres com antibióticos ou outros 
bactericidas e com anticoagulantes, não são suficientemente eficazes para a resolução destes 
problemas [2]. 
Este trabalho de investigação teve como objectivo o desenvolvimento de revestimentos 
antimicrobianos para cateteres intravasculares, de modo a evitar infecções sem induzir a 
formação de trombos. Para tal, péptidos antimicrobianos (AMPs) foram 1) imobilizados 
covalentemente na superfície de filmes de poliuretano (PU) ou 2) incorporados durante a 
formação do filme. O Pellethane 2363-80 AE, foi o PU utilizado neste estudo por ser um dos 
polímeros mais utilizados na produção de cateteres intravasculares devido às suas 
propriedades físicas versáteis e à sua hemocompatibilidade [3]. 
Durante a primeira estratégia, o péptido Cecropin-Melittin (CM) foi covalentemente 
imobilizado na superfície do PU usando nanopartículas de ouro (Au NPs) como agente de 
ligação. A imobilização do CM foi avaliada por espectroscopia de fotoelectrões de raios-X 
(XPS), medição de ângulos de contacto, elipsometria e espectroscopia de infravermelhos por 
transformada de Fourier com reflectância total atenuada (ATR-FTIR) e quantificada por 
espectroscopia Ultravioleta/Visível. A estabilidade do revestimento foi estudada utilizando a 
microbalança de cristal de quartzo com dissipação (QCM-D) em condições de fluxo. Os estudos 
de eficácia foram realizados utilizando uma estirpe de Staphylococcus epidermidis (S. 
epidermidis) produtora de biofilme que foi clinicamente isolada de um cateter infectado [1]. 
A adesão bacteriana e a viabilidade das bactérias aderidas foram quantificadas por 
microscopia de fluorescência. O efeito do CM imobilizado na adesão e ativação de plaquetas 
foi calculado por microscopia electrónica de varrimento (SEM). Estes estudos foram realizados 
na presença e ausência de plasma humano para avaliar a influência da adsorção de proteínas 
na eficácia do revestimento. A adsorção de proteínas do plasma nas superfícies desenvolvidas 
foi quantificada utilizando a QCM-D.  
Os resultados demonstraram que o CM foi imobilizado na superfície de PU com uma 
concentração aproximada de 68 g/cm2. O revestimento com CM revelou-se estável sob 
condições de fluxo e foi capaz de reduzir a adsorção de proteínas do plasma no PU. O CM 
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imobilizado diminuiu a adesão bacteriana ao PU e foi capaz de matar as bactérias aderidas 
mesmo na presença de proteínas do plasma. Este revestimento reduziu a adesão de plaquetas 
ao PU, contudo a pré-adsorção de proteínas do plasma aumentou, de forma não significativa, 
o número de plaquetas aderidas ao material com CM mas diminui o seu grau de ativação. 
Relativamente à segunda estratégia, MSI-78 (1-17) e MSI-78 (2-18), dois pequenos AMPs 
derivados do comercial e muito eficiente pexiganan (MSI-78) [4], foram incorporados em 
filmes de PU durante a sua produção para criar um sistema de libertação de péptidos no local 
da infecção. A atividade antimicrobiana destes filmes contra S. epidermidis foi avaliada na 
presença/ausência de plasma humano através da contagem do numero de bactérias viáveis 
após contacto com a superfície (Unidades formadoras de colónias (CFUs)/mL). 
Os resultados de eficácia demonstram que ambos os filmes com péptidos têm efeito 
bactericida contra esta bactéria mesmo quando produzidos com baixas concentrações de 
péptidos, tanto na presença como na ausência de plasma humano.  
Os resultados desta investigação são bastante promissores sugerindo que a imobilização na 
superfície ou a incorporação de AMPs em biomateriais pode ser uma boa estratégia para 
prevenir infecções sem induzir a formação de trombos.  
 
 
Palavras-chave: cateteres, infecção, formação de trombos, péptidos antimicrobianos 
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Abstract  
Infection and thrombus formation remain the major problem associated with the use of 
long-term intravascular catheters [1]. Strategies based on catheters coated with antibiotics or 
other bactericides and heparin are not enough to solve these problems [2]. 
This research work aims the development of antimicrobial coatings, which can be applied 
in intravascular catheters, to avoid infections without inducing thrombus formation. For that, 
two strategies were followed based on 1) covalent immobilization or 2) physical incorporation 
of Antimicrobial Peptides (AMPs) on polyurethane (PU). Pellethane 2363-80 AE was the PU was 
selected for this study due to its application in the production of intravascular catheters, its 
versatile physical properties and hemocompatibility [3]. 
During the first strategy, the peptide Cecropin-Melittin (CM) was covalently immobilized 
onto the surface of PU films using gold nanoparticles (Au NPs) as binding agent. Surface 
immobilization was evaluated using X-ray photoelectron spectroscopy (XPS), contact angle 
measurements, ellipsometry and ATR-FTIR and CM was quantified using Ultraviolet-Visivel 
spectroscopy analysis. Stability of the CM coatings was evaluated in flow conditions using 
quartz crystal microbalance with dissipation (QCM-D).  
Efficacy studies were performed using a strain of Staphylococcus epidermidis (S. 
epidermidis) that is high slime producer and was isolated from an infected catheter [1]. 
These studies were performed in the presence/absence of human plasma to evaluate the 
influence of plasma proteins adsorption of CM coating efficacy. Plasma protein adsorption to 
the developed surfaces was quantified using QCM-D.  The influence of immobilized CM on 
platelet adhesion and activation was also performed in the presence/absence of human 
plasma.  
Results demonstrated the successful of CM immobilization on PU surface (68 g/cm2). CM 
coating was stable under flow conditions and decreases the adsorption of plasma proteins to 
PU. Immobilized CM was able to decrease bacterial adhesion to PU and to kill adherent 
bacteria even in the presence of plasma proteins. CM coating also decreased platelet 
adhesion to PU. However, adsorbed plasma proteins slightly increased the number of 
adherent platelets on the CM-coating but decreased their degree of activation.  
vi 
Concerning the second strategy, MSI-78 (1-17) and MSI-78 (2-18), two shorter AMPs derived 
from the commercial and very efficient pexiganan (MSI-78) [4], were incorporated in PU films 
during its production to create a local delivery system. The antimicrobial activity of these 
films was evaluated against S. epidermidis in the presence/absence of human plasma by 
(Colony forming units (CFUs)/mL) counting.   
Efficacy results demonstrated that both peptides have bactericidal effect against the 
bacteria even when incorporated in low concentrations, both in presence and absence of 
human plasma. 
The results of this research sound quite promising suggesting that AMPs immobilization or 
incorporation in biomaterials could be a good strategy to prevent infections without inducing 
thrombus formation.  
 
 
Keywords: catheters, infection, thrombus formation, antimicrobial peptides 
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Chapter 1 
General Introduction 
1.1 Motivation and Aim 
 
The major goal of this dissertation is the development of antimicrobial strategies to be 
applied in PU intravascular catheters in order to avoid infections, without inducing thrombus 
formation.  
For that, the peptide CM was covalently immobilized on PU surfaces, using Au NPs as a 
bidding agent.  
At the same time other AMPs, MSI-78 derivatives were incorporated in PU films during 
their production and their bactericidal effect was also studied. 
The use of intravascular catheters is a very common and frequent medical procedure. 
Catheters are used during surgeries, therapeutic delivery, fluids removal, etc. Despite their 
continuous use, complications associated with their long-term utilization still occur, 
commonly in the form of thrombus formation and infections.  
Once implanted in the human body, a biomedical device is quickly surrounded by a layer 
of adsorbed proteins and glycoproteins. These adsorbed proteins can initiate the intrinsic 
coagulation system and induce the adhesion, activation and aggregation of platelets that 
culminate in formation of blood clots. In the most serious scenarios, these clots can be 
released from the catheter, migrate through the blood vessels and cause a distant thrombus 
(thromboembolism), leading to the obstruction of blood vessels creating serious problems that 
may culminate in patient’s dead [5]. More frequently, thrombus formation can also occlude 
the catheter tube requiring its consequent removal/replacement. Conventional strategies to 
prevent thrombus formation include heparin administration. However, haemorrhage 
complications associated with the use of heparin is problematic for some patients, 
particularly for patients with traumas or wounds [6][7].  
Catheter-related infection is also associated with the adsorbed protein layer that will 
mediate bacterial adhesion to the surface of the catheter. This type of infection is usually 
caused by bacteria, present in the patients’ skin or in the hospital environment that after 
adhering to the catheters surface, can generate biofilms highly resistant to conventional 
antibiotic treatments [8].  Moreover, the increasing number of bacteria strains capable to 
become resistant to conventional antibiotics makes catheter-related infections very difficult 
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to treat. Therefore, infection scenario frequently leads to implant removal/replacement, 
which aside from endangering patients’ health also involves important economical costs [9]. 
Because of the limitations of the current strategies available, research has been 
conducted to develop catheters with antimicrobial coatings and better hemocompatibility. 
The immobilization of AMPs, with increased performance over classic antibiotics, on the 
surface of catheters is a promising approach to overcome these issues [10]. Yet, the 
efficiency of these antimicrobial surfaces in contact with human blood and its bacterial 
fighting skills are still poorly studied and require attention.   
 
 
1.2 Structure of the Dissertation 
 
In this dissertation, a complete literature review was prepared, exposing the most 
relevant and recent information on the subject in study.  
The most frequent types of biomaterials used in cardiovascular applications, namely in 
catheters, blood composition and its effect on the hemocompatibility of catheters, along with 
information on thrombus formation are some of the subjects discussed in the Chapter 2. In 
the same chapter is also possible to find information about catheter-related infections and 
the main bacteria involved in those infections, as well as a new strategy to overcome those 
problems, the utilization of AMPs. Types of AMPs, classifications, and mechanisms of actions 
are explored.  
Chapter 3 presents some of the surface characterization techniques used in this work. 
Theoretical fundaments, practical applications and operating mode of the different 
techniques are briefly exposed. 
Materials and methods used in the practical work can be found in Chapter 4 and the 
obtained results in Chapter 5, as well as the discussion of the results acquired. In Chapter 6 
the conclusions and future work are presented. 
 
 
 
Chapter 2 
Literature Review 
2.1 Biomaterials 
 
Biomaterials are a set of materials, natural or synthetic, used in a medical devices to 
diagnose, treat, augment or replace damaged tissues, organs or function of the body [11]. 
They can be inserted in the human body for long periods of time (long-term applications) or 
for small/limited periods (short-term applications). Biomaterials should not induce abnormal 
host responses when implanted, namely inflammation, allergies and early rejection 
associated with toxicity [12], [13].  
Depending on the application, biomaterials may have to be: bioinert, bioactive, 
biodegradable, bioresorbable, biofunctional, etc. Those requirements may also determine the 
physical and mechanical properties of the biomaterial: stiffness, elasticity, resistance to 
stress, composition, density, etc. [14]. Biomaterials should be capable of resisting high 
mechanical solicitation, corrosion, fracture and fatigue. The resistance to constant use and 
varying loading may also be determinant for a long-term success. The highest imposition to a 
biomaterial is that it should not fail as long as the host lives [15]–[17]. 
Biomaterials can be divided in four major classes: (1) composites, (2) ceramics, (3) 
metals, and (4) polymers.  
(1) Composites: materials that contain two or more distinct components. Usually, they are 
divided in two phases, the matrix, which is the bulk continuous phase, and the 
reinforcement, which is the non-continuous phase and usually is formed by materials that 
possess superior mechanical or thermal properties, depending on the demands of the 
application [13], [18].  
(2) Ceramics: non-metallic inorganic materials with limited range of formulations. 
Ceramics possess remarkable properties, great strength and stiffness, high resistance to 
corrosion and wear, and low density and hardness. However, ceramic components may exhibit 
low fracture toughness and sensibility to the presence of cracks or other defects. Because of 
that they are commonly applied in combination with metals [18], [19]. 
(3) Metals: if properly processed, this class of materials provides reliable long term 
implant performance in major load-bearing situations. Metals can be used for several 
cardiovascular applications, namely in stents and cardiac valves. In addition, the good
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electrical conductivity of metals favors their use for neuromuscular stimulation devices such 
as pacemakers [18], [20]. 
(4) Polymers: versatile class of biomaterials due to their inherent flexibility to be 
synthesized or modified to match the physical and mechanical properties of various human 
tissues and organs [21]. Polymers are organic materials, macromolecules that result from 
smaller structural units (monomers) and are often used to replace soft tissue. Indeed, 
polymers are commonly used in the production of cardiovascular devices, including 
intravascular catheters the subject of this work [22].  
 
2.1.1 Polymers for Intravascular Catheters  
 
As said before, polymers are composed of several monomers covalently bonded to form 
long molecular chains. Polymers usually possess oxygen, hydrogen and carbon in their chains.  
Polymers can be of natural or synthetic origins. Natural polymers are the ones we find in 
nature, like cellulose, proteins, polysaccharides, etc., and can be produced by plants, 
animals, and microorganisms. Synthetic polymers are artificially produced in laboratory and 
can be classified in elastomers, thermoplastics and termosets. Elastomers (i.e. rubbers) are 
soft, yet resistant and they can be recycled. Thermoplastics, as polyethylene and 
polyurethane, suffer alterations in their shape under heat conditions being possible to mold 
them with high temperatures. In the other hand, thermosets (i.e. polyester) retain their 
strength and shape even when heated [23][24]. 
Polymers are usually generated from one of two polymerization reactions, addition or 
condensation. In addition reaction, monomers, all equal among them, are added together to 
form a polymer. In condensation the monomers used to form the polymer can be equal or 
different among them. In this reaction, monomers are combined and a simple molecule of 
water, methanol, carbon dioxide or acid chloride is removed [25]. 
If the monomers used to form the polymer are equal, they will form a homopolymer. 
However, if the polymer results from two or more different monomers, it is called a 
copolymer.  
Some of the artificial polymers most used in biomedical applications are 
polytetrafluroethylene, polypropylene, polyamides, polyvinylchloride and poly(ether-
urethane) (i.e. a type of PU) [22].    
As biomaterials, polymers are often applied in the fabrication of cardiovascular devices 
due to their mechanical and physical properties. Polymers are less thrombogenic than metals, 
have low production cost, and, because of their ductility, products with specific shapes can 
be easily manufacture [26]. This way, polymers can be safely used in the production of 
prosthetic heart valves, vascular grafts, artificial heart components, tubing, intra-aortic 
balloons, shunts, percutaneous leads and catheters [27], [28]. 
PU is one of the most used materials in medicine, namely polyetherurethane, since there 
are several types of PU.  PU is not only used in catheters production but in diverse medical 
devices, lead insulators of pacemakers, heart valves, artificial organs, vascular prostheses, 
etc [22].  
This thermoplastic polymer synthesis results from different monomers reaction so, it is 
classified as a copolymer. In its composition there are alternating sections of hard segments 
and soft segments. The hard segments (crystalline) are composed of a isocyanate and a low
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 molecular weight diol chain extender (R1 from Figure 1). Soft segments (amorphous) are 
generally composed of various types of polyols [29]. 
In PU synthesis (Figure 1), first the isocyanate group from the diisocyanate compound 
reacts with the hydroxyl group of the soft segment polyol to form the prepolymer. The 
reaction between the isocyanate groups and the hydroxyl-terminated end groups results in 
urethane linkages. In the second step, the low molecular weight chain extender, diol, is used 
to link the prepolymer segments yielding a high molecular weight polymer [30] [31].  
 
 
Figure 1- Standard two-step reaction to form PU. Adapted from [31] 
. 
The PU used in this research is Pellethane 2363 80 AE, a poly(ether-urethane) that results 
from the reaction of poly(tetramethylene oxide), methylene diphenyl diisocyanate and 1,4-
butanediol. The aromatic isocyanates, as methylene diphenyl diisocyanate, are well known 
for being highly reactive. These groups can be altered by light or temperature and they are 
responsible for PU stiffness. In this case the polyol used was poly(tetramethylene oxide) and 
1,4-butanediol was the diol responsible for chain extender.  
Some of the properties that make PU such a great biomaterial are its durability, 
elasticity, fatigue resistance and compliance, and its acceptance or tolerance by the human 
body [32]. Indeed, since PU was used in the fabrication of catheters, the thickness of the 
walls has been minimized, the flow maximized, the patients' comfort improved with a softer 
insertion, and the thromboresistive properties of the catheters have been ameliorated [33].  
Although, it has been shown that PU have a low microbial colonization rate and better 
hemocompatibility in comparison to other materials [22] infection, thrombosis and 
inflammation related to PU vascular catheters, are still a problem. This is particularly 
important in catheters for long-term application that are often applied in patients with 
chronic diseases, whose immune system has been compromised and in need of prolonged drug 
delivery and fluids removal [34].                              .
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2.1.2   Catheters 
 
Catheters are very thin tubes made of medical grade materials and can be used in a broad 
range of medical functions. These devices are inserted in the human body through cavities or 
through the vascular system, either to treat a disease or to perform a surgical procedure [35]. 
Catheters have many functions in medicine: therapeutic delivery, monitoring cardiovascular 
functions, removal of fluids and opening of blocked conduits [36].  
There are different types of catheters according to the local of application, 
cardiovascular, urological, gastrointestinal, neurovascular and ophthalmic. In cardiovascular 
applications is possible to find pulmonary artery catheters, midline catheters, peripheral 
vascular catheters and central venous catheters, etc. [34]. Peripheral vascular catheters are 
divided in two types, venous and arterial, depending on the vessel where they are inserted. 
Peripheral venous catheters are the most frequently used in clinical practice to access the 
vascular system. Infections related to this sort of catheters have low incidence [34]. To the 
contrary, central venous catheters are responsible for a great number of bloodstream 
infections specially those applied in intensive care units, where most patients have impaired 
immune system [37] [30]. 
Central venous catheters (Figure 2 A) can be divided in: tunneled, non-tunnelled, 
implantable ports and peripherally inserted. Non-tunnelled catheters are made of PU or 
silicone and can be inserted in the neck through the jugular vein or in the peripheral venous 
system through the subclavian vein (Figure 2 B). These are short-term use catheters and do 
not require a surgical procedure. Tunnelled catheters, also made of PU or silicone, are of 
long-term use and are tunnelled surgically under the skin into the cannulated vein [40]. 
Implantable ports are devices that allow vascular access and are made of stable thermoplastic 
polymers (polysulfone) or titanium. These ports are surgically implanted beneath the skin and 
are connected to a catheter tube. The peripherally inserted central venous catheters, also 
made of PU or silicone, are inserted peripherally at or above the antecubital space, into the 
cephalic or basilic vein [38].                            . 
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(B) 
Figure 2- (A) Central venous catheter made of PU, with a triple lumen [42]. (B) Locals of insertion of 
central venous catheters [43]. 
 
The choice for the central venous catheter more appropriate for each situation depends 
on several aspects, the type of therapy or drug to be administered, duration of treatment, 
clinical situation of the patients, etc. Moreover, there are single and multiple lumen 
catheters of all types previously described. Multiple lumen catheters allow different 
medications to be administrated simultaneously without interference with the catheter tube. 
In here, different drugs can be infused in separate lumens, without contact [41].  
 
 
 
2.2 Catheter-Induced Thrombus  
 
After implantation adsorption of proteins and cells to the surface of catheters can 
generate thrombus [44].  
Table 1 describes a series of catheter occlusions classified depending on how and where 
fibrin adheres to the surface.                          .
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Inflammatory reaction may be provoked by a series of events involving proteins, platelets 
and leukocytes that by adsorbing onto the surface of the catheter lead to body responses as 
complement activation, coagulation, cellular recruitments, etc. [45], [46]. All those reactions 
are related to biomaterials, in this case catheters hemocompatibility. 
 
Table 1- Catheter occlusions induced by fibrin deposition (adapted from [47]). 
Thrombotic Catheter Occlusions 
Fibrin Tail Mural Thrombus 
Intraluminal 
Thrombus 
Fibrin Sheath 
Fibrin adheres at the 
end of the catheter 
but is drawn inward, 
blocking the opening 
of the catheter lumen. 
Fibrin from a vessel 
wall adheres to the 
catheter covering the 
surface. 
Fibrin adheres to the 
lumen of the catheter 
when there is blood 
reflux inside the 
catheter. 
Forms when fibrin 
adheres to the 
external catheter 
surface, blocking the 
tip completely. 
    
 
2.2.1 Hemocompatibility 
 
Hemocompatibility relates to the specific interactions between a biomaterial and blood 
[44].  
The human body contains about 5 liters of blood. In its composition red blood cells, 
leukocytes, platelets and plasma (≈ 55% of total blood) can be found (Figure 3). Red blood 
cells exhibit a biconcave disk-like shape and are responsible for the transport of oxygen 
within the bloodstream. White blood cells or leukocytes have very important functions in the 
immune system eliminating invader pathogens by capturing them or by producing antibodies. 
Platelets, also known as thrombocytes, are anucleate cells and their cytoplasm is surrounded 
by a plasmatic membrane. They are involved in blood clot formation. Plasma is the main 
component of blood and is non-cellular. It is a junction of dissolved substances (2%), proteins 
(7%) and water (91%). In the protein portion we can find proteins like albumin, globulin and 
fibrinogen: albumin maintains the osmotic balance of the organism by providing an isotonic
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 solution for cells; globulins are important components of the immune system and bind to 
antigens on the surface of pathogens, defending the body; and fibrinogen has an important 
role in helping the formation of blood clots. The functions of plasma include the transport of 
these substances in the media, as they move throughout the body [48], [49].  
 
Figure 3 – Composition of human blood (adapted from [50]). 
 
The reaction of human blood to a biomaterial is quite complex, it involves different 
mechanisms and elements, going from proteins to cells [51]. A material that does not provoke 
an adverse reaction from blood is categorized as hemocompatible and has higher chances of 
being accepted by the organism. Thus, improving the hemocompatibility of biomaterials has 
become a main concern of the scientific community. Indeed, new biological strategies have 
been engineered to enhance the biomaterials' hemocompatibility; the use of polysaccharides, 
“passivant” proteins, or even thrombotic inhibitors are very common options [52]. 
Hemocompatibility can be evaluated by the level of adhesion of cells to the biomaterial 
during contact with platelets, leukocytes or total blood [53]. The adsorption of plasma 
proteins is also important to define the hemocompatibility of a catheter, since protein 
adsorption on a biomaterial surface can trigger important bioresponses: plasma enzymes 
cascade activation (complement, fibrinolytic and coagulation systems), platelet activation, 
leukocyte activation or blood aggregation, responsible for thrombosis [54]. Adsorption of 
plasma proteins can also promote bacterial adhesion to polymeric surfaces, generating 
biofilms and, consequently, infections that culminate in the biomaterial removal or 
substitution [55].  
 
2.2.2 Plasma Proteins 
 
Plasma is the biggest component of the human blood. In its composition there are several 
proteins, including albumin, fibrinogen, globulins and other regulatory proteins, such as 
enzymes, proenzymes, and hormones. 
Human serum albumin, present in plasma in a concentration around 40 mg/mL in human 
adults, is the most abundant plasma protein representing about 60% of total protein 
composition (Figure 4 A). This protein is considered a very important mediator in biomaterial 
applications. Indeed, albumin has the ability to prevent bacterial and cell/platelet adhesion 
on polymer, ceramic and metal surfaces [56],  by binding directly to bacteria or by increasing 
the hydrophilicity of the surface (albumin adsorbs preferentially onto hydrophobic surfaces). 
This way, adsorbed albumin reduces surface-blood interactions in biomaterials becoming an
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 important agent in hemocompatibility, fighting inflammation, infection and thrombus 
formation [57]. 
Fibrinogen, also known as factor I, is a glycoprotein produced in the liver in a plasmatic 
concentration of 2-4 g/L (Figure 4 B) [58][59]. 
Fibrinogen, by the action of thrombin, can be converted into fibrin to form blood clots 
during hemorrhagic accidents. It also contributes to the activation and aggregation of 
platelets [51]. Because of that, fibrinogen adsorption onto biomaterial surfaces is a limiting 
factor of hemocompatibily. Moreover, it has been shown that fibrinogen may induce 
inflammatory events on biomaterial surfaces by increasing the recruitment and adhesion of 
leukocytes [60]. 
 
(A)                                                                                             (B) 
Figure 4- (A) Structure of human serum albumin [61] and (B) human fibrinogen [62]. 
 
2.2.3 Coagulation System 
 
The coagulation system is responsible for maintaining hemostasis, or in other words to 
suspend hemorrhagic events. This process is directly correlated with the recruitment, 
activation and aggregation of platelets [63]. Indeed, when an injury is suffered and 
hemorrhage occurs, coagulation factors are activated to stop the bleeding by forming blood 
clots, coagulation [64]. Those clots are composed by a network of fibrin that retains 
platelets, blood cells and even fluids. 
Coagulation system can also be activated by contact with a foreign surface, a biomaterial. 
The activation of coagulation proteins by a biomaterial starts with adsorption of plasma 
proteins, namely contact phase proteins as Hageman factor (factor XII), prekallikrein or high 
molecular weight kininogen (HMWK), on its surface. Factor XII when activated is also involved 
in the initiation of the fibrinolytic system (section 2.2.3) and the classic pathway in 
complement system (section 2.2.4) [65], [66]. 
Based on the event that promotes system activation, coagulation may occur in two ways: 
by intrinsic pathway or by extrinsic pathway (Figure 5). Intrinsic pathway is initiated when 
factor XII contacts with a material surface, particularly negatively charged surfaces like glass 
and some biomaterials by surface-mediated reactions. Although, factor XII can also be 
activated by contacting with activated platelets and damaged tissue. Extrinsic pathway is 
triggered by substances extrinsic to blood. Its stars when cells expressing tissue factor (TF) on 
its surface are exposed to blood components during an injury. TF will react with factor VII
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 present in blood plasma, activate it into factor VIIa and forming a complex TF/factor VIIa 
that on its turn will activate factor IX and factor X [67].  
Injured tissues or vessels can activate their coagulation factors by different ways; still, all 
result in prothrombinase formation. Prothrombinase converts prothrombin in thrombin, which 
not only converts fibrinogen into fibrin but also has a retro-positive action mechanism that 
allows for more thrombin to be produced. Prothrombinase and thrombin can also stimulate 
factor XIII activation that has an important role in stabilizing fibrin clot as schematized in 
Figure 5 [68]. 
 
 
 
Figure 5- Pathways of activation of coagulation cascade (based on [18]). 
 
When a vascular vessel suffers a small rupture, platelets may accumulate at the site to 
block the hemorrhage and maintain the integrity of the circulatory system. This process 
involves several steps and starts with the adhesion of platelets to the collagen exposed by the 
injured vase. This interaction is mediated by the von Willebrand factor (vWF), a blood 
glycoprotein that acts like a bridge between platelets and collagen promoting its binding. 
After binding to collagen, platelets are activated and release compounds like thromboxane 
that stimulate other platelets to become active as well. This way, their surface receptors 
bind to fibrinogen that promotes platelet-platelet binding and, consequently, the formation 
of platelet agglomerates (Figure 8) [69], [70].                                 .
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2.2.4 Fibrinolytic System 
 
Without a control mechanism, coagulation would spread throughout the organism leading 
to acute incidents. To prevent that, natural anticoagulants present in the blood act to 
suppress the coagulation factor activity and hinder blood clots continuous formation. Some of 
those anticoagulants are anti-thrombin, heparin and prostaciclins [71] [72]. 
The fibrinolytic system, represented in Figure 6, is responsible for blood clot degradation 
also contributing for coagulation control. In this process, thrombin, factor XII, tecidular 
plasminogen activator and other enzymes activate the plasminogen present in the blood 
which converts into plasmin, an enzyme that hydrolyzes fibrin. By the action of plasmin, 
fibrin molecules are fractionated releasing small pieces of clot to be phagocyted or removed 
by blood [73]. 
 
 
 
Figure 6- Fibrinolytic System (based on [18]). 
 
2.2.5 Complement System 
The complement plays an important role as a defense mechanism of the human organism, 
by participating in the inflammatory response and by being part of the innate immune 
system. It is composed of several plasmatic and membrane proteins synthesized mostly by the 
liver, monocytes, macrophages and fibroblasts. Those proteins are responsible for many 
biological events associated with the immune response, opsonization, chemotaxis and cellular 
lysis, for instance. As may be seen in Figure 7, the complement is divided in 9 components 
(C1-C9), with major (b) and minor (a) fragments and can be activated in three different ways: 
lectine pathway, classic pathway and alternative pathway.  
The alternative pathway starts with the adsorption of C3 proteins on foreign surfaces, as 
bacterial components and biomaterial surfaces. This is the most common pathway applied to 
biomaterial surfaces. However, the classical pathway can also be activated by biomaterials 
through factor XIIa fragments that are able to activate component C1.  
All pathways lead to the formation of membrane attack complexes that start with a C5b 
component and end with the addition of C9, resulting in a canal constituted by polymerized 
C9 molecules that allow the passage of water and electrolytes through the cell membrane and 
lead to osmotic lyses [74]. 
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 To summarize, complement system activation results in cell lysis when the membrane 
attack complex is inserted in cell membrane. 
Complement activation also releases several components as C3a, C4a and C5a involved in 
the inflammatory processes by increasing vascular permeability and activating leukocytes. 
C3b component may also induce the adhesion of leukocytes when bound to foreign surfaces 
[75].  
Coagulation system and complement system interact between them modulating each 
other’s activity. This interaction depends of some coagulation system’ proteins that act on 
complement system provoking a response or vice-versa. For example, thrombin can activate 
fragments C3, C5 and C6 [65]. 
 
 
Figure 7- Different pathways of complement system [76]. 
 
2.2.6 Interaction of Blood Cells with Biomaterials 
 
Plasma proteins adsorption on biomaterials is a complex process that may involve the 
coagulation and complement systems. Platelets and leukocytes are the main cells interfering 
with the blood cells interaction with the biomaterials [5]. 
 
2.2.6.1 Platelets Adhesion and Activation 
 
Platelets are annucleate cells present in human blood in a concentration of 2.5x105 
platelets/µL. They are small in size (3 µm) and exhibit a disc-like shape when inactive. These 
cells are formed in the red bone marrow by megakaryocyte cells that, from time to time, 
break and release pieces of membranes that eventually will become platelets [77].
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Platelets are responsible for blood clotting and the formation of scars. At their surface, 
platelets have glycoproteins acting like receptors that recognize other platelets and 
molecules and allow the formation of platelet aggregates [78]. Fibrinogen is one of the most 
important molecules which platelets can bind to since it allows platelets to aggregate with 
each other. Fibrinogen has two RGD (Arg-Gly-Asp) sequences in the subunit Aα and a 
dodecapeptide (sequence HILGGAKQAGDV) in the carboxyl terminus (or C-terminal) of the 
subunit γ that are involved in the binding to the integrin GP IIb/IIIa in platelets [79]. When 
fibrinogen adsorbs to a surface it acquires a different conformation by exposing the 
dodecapeptide in the γ chain. This way, platelets can bind to surface adsorbed fibrinogen 
(Figure 8). Thus, conformation of adsorbed fibrinogen will mediate platelet adhesion to 
biomaterials being conformation more important than the amount of adsorbed fibrinogen 
[51]. Inactive platelets, however, cannot bind to soluble fibrinogen in the bloodstream unless 
they are exposed to thrombin, collagen or other agonist; only then, integrin GP IIb/IIIa 
becomes an effective receptor to bind to fibrinogen.  
Active platelets have different shapes according to the level of activity expressed. 
Depending on that, they can be classified in round, dendritic, spread dendritic, spread, and 
fully spread, with round representing inactive or less active platelets and fully spread 
representing the maximum state of platelet activity (a figure with platelets states of 
activation can be consulted in Figure 30, section 4.4). The activation and adhesion of 
platelets to biomaterial surfaces is highly mediated by fibrinogen; yet, other proteins, like 
fibronectin and vitronectin, can be involved in hemostasis as well [80]. 
Activated platelets secret polyphosphates that activates factor XII, initiating fibrin 
production by intrinsic pathway of coagulation, leading to thrombus formation [81]. This way, 
to avoid platelets activation is so or even more important than prevent platelets adhesion. 
Also, recent studies have shown that platelets can interact with bacteria, promoting its 
adhesion, so if a surface leads to platelet adhesion it can also consequently lead to bacterial 
adhesion, with infection scenario [82].                                   .
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Figure 8- Platelet adhesion, activation and aggregation processes [83]. 
 
2.2.6.2 Leukocytes Adhesion and Activation 
 
Leukocytes are white blood cells present in peripheral blood and extremely important to 
the immune system. Depending on their functions leukocytes can be divided in monocytes, 
neutrophiles, eosinophiles and basophiles, all responsible for ingesting and eliminating 
external particles. Lymphocytes are another type of leukocytes and display a more specific 
response against foreign antigens [74].  
Since leukocytes integrate the immune system, when a biomaterial is implanted an 
inflammatory response is triggered to defend the organism against the foreign body. In fact, 
this inflammatory process can be so aggressive that biomaterials are destroyed by the 
leukocytes [84]. 
Adhesion of leukocytes to biomaterial surfaces depends on various surface properties such 
as wettability, composition and charge. Some other factors as protein adsorption, platelets 
and bacteria adhesion and complement activation also influence leukocyte adhesion. 
Leukocytes can recognize proteins adsorbed onto a surface and bind. Indeed, when proteins 
adsorb to a biomaterial surface they expose ligands recognized by the leukocyte receptors. 
One of the proteins affecting leukocyte inflammatory response is fibrinogen. Fibrinogen acts 
by increasing leukocyte recruitment and adhesion to implanted biomaterial [85]. Adhesion of 
leukocytes to biomaterials can lead to other problems aside from inflammation: formation 
and detachment of microthrombus through platelet-leukocyte interactions, release of 
leukocyte products that can cause systemic vascular reactions and leukocyte spreading 
through the organism, are some of the many [86].                                      .
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2.3 Catheter-Related Infections 
 
Bacterial adhesion is a very serious threat to the patient's health during implantation. 
Application of catheters or other implants, for instance shunts, stents or heart valves, is a 
common and efficient procedure in the medical field; however, the danger of infections 
raises the need for fast and durable solutions [87]. 
The protein layer that surrounds a biomaterial after implantation  works as ligands to cell 
and bacteria membrane receptors, which compete with each other for the surface of the 
biomedical device [55]. When bacteria adhere to a material’s surface a series of reactions 
take place and induce the formation of a biofilm which consequently lead to infections. From 
these infections a variety of problems can arise including implant removal, prolonged 
hospitalization or even dead. Intravascular catheters are a leading source of infections in 
cardiovascular systems, especially among critically ill patients and cancer patients [88]. 
Despite all hygienic care strategies implemented in the last years to reduce infection 
incidence, mortality is still very high. More than 250,000 vascular catheter-related infections 
occur annually in the USA with a mortality ranging from 12% to 25% [37]. A study from Spain 
revealed a mortality rate of 22.4% in intensive care patients that developed catheter-related 
infections [89]. 
There are two different types of catheter-related infections: local and systemic. Local 
catheter infections are exit site infections and look like a tunnel. These affect only the 
surrounding zone of catheter insertion and are very often characterized by erythema, 
warmth, pain, induration, etc. Systemic catheter infections affect the whole body and can 
spread by transport of microorganisms in the bloodstream. Lately, systemic infections have 
been indicated as the cause of septicemia, a severe general infection, characterized by 
symptoms as fever, chills and hypotension stimulated in the presence of bacteraemia or 
fungaemia [90]. In this work we focus in Staphylococcus since these are the most frequently 
species found in infected intravascular catheters (Figure 9). 
 
 
Figure 9- Incidence of microorganisms in central venous catheter-related infections (based on [91]).
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2.3.1 Bacterial Adhesion and Biofilm Formation 
 
The difficulty to eliminate microorganisms responsible for intravascular catheter-related 
infections is many times correlated with the capacity of the microorganisms to form biofilms 
[92]. 
Bacteria have the capacity to specific adhere to the surface of a biomaterial mostly 
because of the proteins that adsorbs on the material, once it is implanted. Binding between 
bacteria and surface is mediated by adhesins, bacteria appendices (fimbriae) that promote 
adhesion to other cells or surfaces by binding to specific receptors. 
Biofilm formation is divided in three main phases, initial phase, second phase and final 
phase (Figure 10). Initial phase is physically reversible and is characterized by 
physicochemical interactions between bacteria and surface [93]. It starts with transport of 
bacteria to the surface via diffusion, convection and/or bacteria active movement. When in 
the surface, bacteria adhere reversibly by means of electrostatic, ionic or van der Walls 
interactions. This binding, however, can be broken by the action of shear forces or bacteria 
active movement [94].  
Bacterial adherence is affected by different factors as bacteria strain, biomaterial surface 
properties, and environmental factors. The last two are perhaps the most influent factors and 
those we can better alter or control to generate new and improved medical devices for 
patient care. Factors as surface hydrophilicity or roughness can influence bacterial adhesion. 
Rough surfaces, because of the presence of furrows, stimulate bacterial adhesion compared 
to smooth surfaces. Environmental factors as temperature, antibiotics presence, exposure 
time, bacteria concentration, and the presence of certain proteins can be as well crucial 
[95][96].   
The second phase is irreversible, time dependent and characterized by cellular and 
molecular interactions. In this phase, a set of specific interactions happen between bacteria 
adhesins, as fimbriae, pili or capsules, and specific surface structures, culminating in a 
irreversible fixation. In the end of the second phase, colonization takes place. Here, bacteria 
bind to the surface and start to replicate in new bacteria forming clusters capable of 
originating biofilms.  
Final phase, or phase 3 correspond to biofilm formation and maturation. A biofilm is 
generated when microorganisms adhere to a surface, tissue or inanimate material, replicate 
and secrete insoluble gelatinous exopolymers. Through these, they form a three-dimensional 
and well organized matrix composed of polysaccharides, proteins, nucleic acids and lipids, 
which are produced by them or by the surrounding cells. The resultant matrix layer, named 
slime, hinders antibiotics access to local infection and phagocytosis by immune cells. This 
slime is highly resistant even in non ideal environmental conditions: alterations of pH, 
osmotic shock, UV radiation, flow conditions, and most importantly antibiotic and biocidal 
substances, making bacteria more resistant when organized in biofilms [97].  
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Figure 10- Different phases of biofilm formation and maturation (adapted from [100]). 
 
Moreover, microorganisms growing in biofilms are less susceptible to antibiotics and host 
defenses, because when organized in biofilms, bacteria remain in latency and most of 
antibiotics are only effective against metabolically active bacteria. Also some biofilms are 
constituted by a diverse community of bacteria and antibiotics are effective specific against 
specific bacteria. These are the main factors that increase bacteria resistance. In fact, 
studies have shown that sub-lethal doses of antibiotics can actually enhance biofilm formation 
[98]. Nosocomial infections are one of the main causes of biofilms formation since they can 
develop and grow in medical devices or equipments [99]. Often, biofilms lead to material 
deterioration or accelerate their corrosion, products contamination, decrease in frictional 
fluid resistance, etc., which may destroy specific medical devices with consequences to the 
patients. Also, they can provoke very harmful and serious responses from the patient's 
organism as complement activation, cytokines release and free radicals production. Biofilms 
are very dangerous to the organism, since they not only are a source of infection but can also 
induce thromboembolisms by releasing from the surface [45].  
 
2.3.2 Staphylococcus  
 
Staphylococcus is a group of bacteria that belongs to the Micrococcaceae family. The 
name Staphylococcus comes from the Greek and relates to the cocci arrangement of these 
microorganisms. Under microscope observation, these bacteria look like a bunch of little 
round berries, all close together with a purple coloration since they are Gram-positive. 
The main difference between Gram positive and Gram negative bacteria is related to its 
cell wall (Figure 11). The Gram stain method uses crystal violet dye and allows differentiating 
bacteria in Gram positive and Gram negative according to cell walls characteristics [101]. 
Gram positive bacteria have a layer rich in peptidoglycans with low lipid and lipoprotein 
content, becoming more resistant, less susceptible to dissolution. The high content in 
peptidoglycans and magnesium on its wall is what permits to retain crystal violet dye.  
On the other hand, Gram negative bacteria have a thin peptidoglycan layer and are rich in 
lipids and lipoproteins due to existence of an extra outer membrane. This type do no retain 
crystal violet due to the absence of magnesium and few peptidoglycans on its wall, so 
bacteria become colored by red or pink [102][103].                                                              .
19 
 
 
 
 
                    (A)                                                                        (B) 
Figure 11- Cell wall of Gram negative (A) and Gram positive bacteria (B). 
 
 Aside from being Gram-positive, staphylococcus are facultative anaerobic and are usually 
encapsulated. This capsule is formed by a polysaccharide layer and protects Staphylococcus 
against immunological defenses, such as leukocytes and phagocytes. It also can facilitate 
bacteria adhesion to biomaterials as joints, prosthetic valves and catheters. The diameter of 
Staphylococcus varies between 0.5-1.5 µm. These bacteria are non-motile (incapable of 
movement) and catalase positive.  
There are a total of twenty seven species of Staphylococcus but only fourteen species and 
two subspecies can be found in humans. They usually grow in the skin and mucous 
membranes. The species most associated with infection cases in humans are the S. aureus, S. 
epidermidis, S. haemolyticus, S. lugdunensis, S. saprophyticus and S. schleiferi. All of these 
species are coagulase negative except for S. aureus that is coagulase positive, meaning that it 
has the ability to produce the enzyme coagulase.  
Staphylococcus are microorganisms that easily gain resistance to antimicrobials and are 
then capable of transmitting that same resistance to other bacteria. For instance, the 
resistance of Staphylococcus to penicillin is mediated by the production of β-lactamase that 
hydrolyzes the β-lactam ring of penicillin. 
Portugal, in 2008, was the only European country whose methiciline-resistant S. aureus 
prevalence in hospitals was over 50% [104]. 
 In order to solve this problem, semi-synthetic penicillins resistant to β-lactamase 
hydrolysis were developed; still, bacteria became resistant to this sort of antibiotics by 
altering the antibiotic target sites (penicillin-binding proteins). To treat efficiently these 
infections antibiograms are conducted to understand which drug is more efficient against a 
specific bacteria [105].  
Because of the variety of Staphylococcus species that can affect humans, a wide number 
of diseases have their origin in these microorganisms [106].  
Catheter contamination by Staphylococcus is frequently a cause of bacteremia since 
microorganisms have continuous access to the bloodstream, this way spreading infections 
throughout the entire organism [107]. For the purpose of this research we will focus our 
attention on S. epidermidis bacteria, one of the most frequent bacteria to cause catheter 
infections [1].                                                                           .
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2.3.2.1 S. epidermidis 
 
S. epidermidis (Figure 12) is the most frequently specie of staphylococcus to be isolated 
from human epithelia. It colonizes human skin and mucosa surfaces and as all the other 
staphylococcus species is gram-positive.  This specie, in particular belongs to the coagulase-
negative group of staphylococcus, since it lacks the enzyme coagulase [108][109]. 
This microorganism can cause nosocomial infections very easily because of its presence in 
the skin and mucosa, which facilitates its entrance in the body via injuries or implanted 
medical devices [110]. S. epidermidis has the ability to form biofilms on or within the medical 
devices, whose elimination and treatment are very complicated. This specie can relate well 
with catheters in the matter of infections since it has the capacity to produce slimes, that 
prevents bacteria from phagocyte ingestion [111] . 
S. epidermidis now accounts for at least 22% of bloodstream infections in intensive care 
unit patients in the USA, which occur in at least 4–5/1000 central venous catheter insertions 
[112]. This is one of the main reasons why this staphylococcus specie was chosen to be use in 
this research. 
 
 
Figure 12- Staphylococcus epidermidis. Original scanning electron microscopy (SEM) image at 
magnification 10,000x. 
 
2.3.3 Strategies to Prevent and Treat Catheter-Related Infections  
 
All the problems associated with bacterial adhesion to biomaterials, and consequent 
biofilm formation, has increased the scientific research to find new and better strategies to 
avoid and treat infections.  
The development of biomaterials with anti-infective properties is one of the most studied 
strategies to prevent infections associated with medical devices. Among these anti-infection 
biomaterials we can find materials with: 
 i) antifouling properties and with  
 ii) bactericidal activity,  
 killing by contact or  
 delivering antibacterial compounds [17][14]                                                 .
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(A)                                         (B)                                          (C) 
Figure 13- Surfaces with bactericidal effect by direct contact (B) and by release from the surface (C). 
(A) Surface with non-fouling properties. Adapted from [113]. 
 
i) Biomaterials with antiadhesive properties 
There are several ways to produce biomaterials with anti-adhesive properties acting at 
level of surface modification.  
Surfaces with high negative charge, polyanionic surfaces, have the ability to repulse 
bacteria with polianionic glycocalice (most of gram-positive bacteria) through electrostatic 
interactions, however, gram-negative bacteria have policationic glycocalices, so this surface 
modification mechanism is only effective against a specific number of bacteria [7] .  
Also coating with polymeric brushes can prevent bacterial adhesion, by avoid bacteria to 
directly contact with the surface. Usually, antifouling surfaces, such as the ones with polymer 
brushes (Figure 13 A), are hydrophilic, however, they can also be superhydrophobic. 
Superhydrophobic surfaces act through a wetting mechanism that prevents the contact 
between bacteria and attachment points on the material [114]. Also zwitterionic surfaces can 
have anti-fouling properties avoiding proteins adsorption and consequent bacterial adhesion 
[115],[116]. 
Protein adsorption on biomaterial is an initial step to bacterial adhesion, so the 
biomaterial’s surface can be modified to avoid such so. This process can be achieved by 
reducing the protein-surface interaction or by decreasing the rate of protein adsorption on 
the surface. Also the surfaces can be previously adsorbed with selected molecules that can 
modify surface hydrophobicity or hydrophilicity  as albumin that prevents bacterial adhesion, 
as explained in section 2.2.2 [117].  
 
ii) Biomaterials with bactericidal activity  
There are several materials with intrinsic antibacterial properties, as silver, zinc, cooper, 
or chitosan. Nevertheless, materials can also be modified to acquire bactericidal activity [17]. 
Antibacterial coatings are an example, chemical or physical changes on the surface can 
produce bactericidal effect, however, is important to maintain a balance between 
antibacterial properties and biocompatibility of the coating, since it will be in contact with 
host’s tissues or blood [7].  
 Killing by contact 
Antibacterial coatings can fixate certain antibacterial molecules on the material surface 
or can release those molecules. Several coatings can be classified as “contact biocides” since
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 they use some substances (e.g. antimicrobial peptides) that kill by contacting with the 
bacteria with no need to release from the surface [118] [119].  
 Delivering antibacterial compounds 
However, there are coatings that release substances (e.g. nitric oxide) with antibacterial 
properties that will interact with bacteria in a larger distance from the bulk. It is important, 
though, that this release into the surrounding tissues be controlled to avoid toxic effects 
[120]. In (Figure 13 B and C) is possible to see a contact killing surface and a biocidal 
releasing surface. 
About catheter-related infections there are several strategies to prevent and treat them, 
however, they are not very effective. Infections caused by catheters are often treated with 
antibiotics. However, this has become quite a challenge because of the increased resistance 
of bacteria to antibiotics. Yet, the most frequent form of treatment of catheter-related 
infections continues to require the device removal or substitution [106]. 
 In some hospitals heparin is administrated to patients using central venous catheters to 
prevent deep vein thrombosis and pulmonary embolism. However, as explained before, it can 
be dangerous to some patients. To avoid these situations, several strategies have been 
proposed to prevent catheter-related infections: cutaneous antisepsis using povidone-iodine 
for local catheter insertion, maximum sterile barrier precautions as wearing sterile gloves, 
cap and gown and more recently the use of antimicrobial coated catheters [38]. 
Antimicrobial coated catheters are catheters on which an antimicrobial agent has been 
coated to its surface to prevent or minimize adherence of microbial organisms. There are 
various types of antimicrobial catheters that can be applied according to each situation. 
Antiseptic catheters, for instance, are central venous catheters made of PU and coated with 
chlorhexidine and sulfadiazine silver. Another type, silver-impregnated catheters use a 
mechanism in which silver, platinum and carbon are incorporated in the catheter allowing 
topical silver ion release [96]. Antibiotic-coated catheters with minocycline and rifampicin 
are perhaps the most frequently used; still, they present a major limitation since bacterial 
resistance to the antibiotics increases in long-term applications [121].  
To overcome this problem several studies have been made to find viable alternatives to 
antibiotics. Catheters coated with antimicrobial peptides (AMPs) could be a promising 
strategy [36].  
 
 
2.4 Antimicrobial Peptides (AMPs) 
 
Antimicrobial peptides (AMPs) are a class of peptides with a broad activity against 
bacteria, virus and fungus. These peptides provide a non-specific defense against a broad 
spectrum of invaders of their host, acting like a component of innate immune system. These 
peptides are produced by various animal and plants [122]. However, they can also be 
produced synthetically, so is possible to divide AMPs in natural and synthetic. 
AMPs are small peptides (with five to one hundred amino acids). They are often cationic 
molecules due to the excess of lysine, arginin and histidine, although, recent studies have 
proved the existence of anionic, negatively charged AMPs [123].  
Most AMPs are amphipathic, meaning that they have both hydrophilic and hydrophobic 
faces. Amphipathicity affects mostly the binding to microbial surfaces, since it is necessary a 
strong partition into the membrane interface [124]. Amphipatic α-helix structure is one of the
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 most effective interacting with biomembranes, easily permeabilizing microbials. This way, 
amphipathic helicity influences peptide activity. Solubility and some mediators as proteases, 
metals, salts or even chemical modifications can also regulate peptide activity [125]. 
There are several types of AMPs but it is possible to group them in four main classes, 
according to its structural diversity: α-helix, β-sheet, extended and loop (Figure 14). The 
most common types are α-helix and β-sheet, the first is formed only when the peptide 
contacts with a membrane, and the second is stabilized by 2-4 disulfide bonds. The less 
common, extended and loop, display a curved form in response to a simple disulfide bond or 
the presence of proline residues in its structure [126], [127].  
 
 
Figure 14- Possible structures of AMPs. Adapted from [131].  
 
AMPs are frequently found in plants and animals but can also be produced by prokaryotes 
as bacteria, and by fungi, protozoan and insects. Over than 5000 AMPs have been discovered 
or synthesized. Natural AMPs are those found in nature, produced by organisms. Synthetic 
AMPs are produced artificially through chemical synthesis or recombinant expression. Since 
they are composed of amino acids it is relatively easy to immobilize and modify their 
structure, being possible to obtain new AMPs with improved stability and greater range of 
targets [128].  
There are several eukaryotic cells capable of producing AMPs, like epithelial cells from 
gastrointestinal and genitourinary systems, phagocytes and lymphocytes. In animals, AMPs are 
part of the innate immunity generated by the immune system. They can be found mostly on 
the tissues exposed to airborne pathogens. In plants they form a system of defense, similar to 
the innate immunity in animals, that protects the organism from pathogens and plague 
attacks [129]. Humans also have some AMPs in their organism, as α-defensin 6, β-defensin 
120, chemokine CCL24, chemokine CCL26 and human ribonuclease 6. These peptides or 
proteins are effective against several pathogens (i.e. bacteria). Upon invasion, AMPs 
production can be stimulated; for example, cathelicidin, a human antimicrobial peptide, is 
produced by skin fat cells after S.aureus infection [130].                                                 .
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2.4.1 Mechanisms of Action 
 
In contrast with the mechanisms of action of classic antibiotics, which are based in slow 
processes of enzymatic inhibition and target specific cellular activities as DNA or protein 
synthesis, AMPs target the lipopolysaccharide layer on the cells membrane which is similar to 
all microorganisms. AMPs are very quick during killing process; they can kill microorganisms in 
seconds after contact with the cell membrane. They may also display synergistic effects with 
antibiotics by increasing antibiotic activity above the antibiotic individual effect [132]. 
AMPs can be classified in four main types according to the target microorganism: antiviral 
peptides, antifungal peptides, antiparasitic peptides and antibacterial peptides. 
Antiviral peptides can kill viruses by integrating the host cell membrane or viral envelopes 
and causing membrane instability. This membrane instability makes viruses incapable of 
infecting host cells. AMPs can also act by blocking viral receptors, by preventing viruses to 
bind to viral receptors on the cell membrane already occupied with AMPs [133]. 
Antifungal peptides can neutralize fungi by targeting and binding to intracellular 
components or the cell wall, as chitin for example, disrupting the integrity of the fungal 
membrane, and forming pores or increasing permeabilization of the plasma membrane [134].  
Antiparasitic peptides are a smaller group which comprises AMPs as magainin and 
cathelicidin. They kill parasites by directly interacting with the cell membrane and forming 
pores, like the previous categories of AMPs, even though some parasitic microorganisms are 
multicellular [135]. 
Antibacterial peptides are the most studied group of AMPs. Most of them are cationic or 
amphipathic, and target the bacteria cell membrane causing disruption. Those with 
hydrophilic and hydrophobic domains can bind both to lipid components and phospholipid 
groups. Most AMPs that interact with the bacteria surface cause disturbs in the structure of 
the lipid bilayer and may lead to the cell lyses [136]. Those AMPs positively charged are 
attracted to the anionic  surface of the bacteria membranes causing electrostatic interactions 
that on its turn may lead to membrane disruption [137].  
Initially the peptides cover the bacteria membrane and change their orientation from 
parallel to perpendicular to the membrane surface. Next, they form pores on the membrane 
eventually leading to its disruption. Three models (Figure 15) explain the mechanism of 
action of membrane-active AMPs: 
(1) The carpet model: there is formation of an extensive hole in lipid layer that bends 
back on itself causing lysis of the cell. 
(2) The toroidal pore model: peptides insert into the membrane and form clusters that in 
association with water molecules create channels that allow leakage of ions and 
molecules to the outside and peptide entrance to the inside, exerting their killing 
activities. 
(3) The barrel-stave model: peptides interact laterally with each others to form specific 
barrel-like structures that line amphipathic transmembranes pores, hydrophobic tails 
at the inside of the phospholipid bilayer and the hydrophilic side-chains oriented 
inward into the water-filled pore [138][139]. 
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Figure 15- Mechanisms of action of membrane-active AMPs: carpet, toroidal pore and barrel-stave 
model [138]. 
 
Studies have shown that AMPs can kill bacteria not only by disrupting its membrane but 
also by inhibiting some important pathways inside the cells, such as DNA replication and 
protein synthesis, and by interacting with some intracellular components [140], [141].  
AMPs also have the ability to inhibit some functional proteins on the cell membrane, 
increasing the velocity and efficacy of AMPs activity in killing microorganisms. Indeed, 
because those proteins have several main functions as nutrients transportation, respiration, 
intercellular communication, etc., this protein inhibition associated with membrane 
disruption accelerates the AMPs' killing effect [142]. AMPs can also kill antibiotic resistant 
bacteria and some are even effective against more than one class of microorganisms[143]. 
Indolicidin, for instance, kills bacteria, fungi and viruses; such a broad spectrum of action is a 
great advantage over single target antibiotics [133]. 
 
2.4.2 AMPs Immobilization  
 
AMPs are usually immobilized on solid surfaces chemically or physically. On the chemical 
methods we can find covalent immobilization and on physical methods the layer-by-layer 
assembly and physical adsorption [144]. Although, those are the most frequent types of AMPs 
immobilization there are some other strategies already tested as the incorporation in 
nanoparticles acting as delivery systems [145]. 
Physical methods are based on hydrogen bonds, dipole interactions (van der Waals’ force 
or London dispersion force), and hydrophobic or ionic interactions between AMPs and 
surfaces. Simple physical adsorption is one of the easiest ways to immobilized peptides, 
however the antimicrobial effect at long term application may not be very effective [146]. 
Also incorporation techniques were tested in order to directly incorporate AMPs in the 
biomaterial as collagen matrix  [147] or a calcium-phosphate bone cement [148].   
Layer-by-layer is a physical immobilization method commonly used and in this case the 
AMPs are embedded between two polyionic polymers. The polymers not only hold the peptide 
on the inside but they also bind to the solid surface, forming a sandwich (polyanion-peptide-
polycation) that can have several layers. This method can only be applied with highly charged 
and water soluble AMPs, a less frequent type. An advantage of this method is that it allows a 
high and controllable loading of the AMP on the surface. However, since the AMPs will not be 
in direct contact with the surrounding bulk there is a need for the peptides to release through
26 
 
 diffusion. This diffusion through the membrane process could be complicated, besides, 
bacteria biding on the top layer of the sandwich may block the exit of AMPs from the inside of 
the matrix [123] [149].  
In covalent immobilization, AMPs chemically react with a given surface to form stable and 
non-leaching antimicrobial coatings with increased time of duration [150]. Not all surfaces 
have the ability to directly react with AMPs, so it may be necessary some surface treatment 
to introduce the desired functional groups that will allow the grafting of the peptides. A 
process frequently used functionalized resins such as Poly(ethylene glycol) (PEG) or other 
polymeric ‘brushes’ that presents reactive groups suitable for AMPs covalent immobilization. 
Those PEG spacers, will allow rapid and free orientations of bound AMPs promoting peptide–
bacteria interactions, and enhancing the protective performance of the bound peptide layer 
on the surface [151]. However, there are some concerns as the possibility of polymer 
degradation reactions resulting in PEG chain cleavage and thus the release of bound AMPs.  
Covalent immobilization has some advantages as an increased long-term stability and 
decreased toxicity. However, this immobilization method efficiency also depends on several 
factors such as chemical coupling strategy used, length and flexibility of the spacer, peptide 
surface concentration and peptide orientation [152].  
The use of a spacer on covalent immobilization can be very advantageous. For example, 
PEG immobilization can give the surface non-fouling characteristics, forming a non-adhesive 
surface, avoiding bacterial adhesion. Actually, the utilization of a spacer could be a crucial 
step to obtain an efficient antimicrobial activity of the AMP. Studies have shown that some 
peptides are only effective when a PEG spacer was used [153][154]. 
Peptide concentration on the surface also affects its bactericidal activity; however there 
is some controversy about this subject. Although some studies defends that peptide 
concentration have less impact that spacer influence, for example, some other studies defend 
that a higher peptide concentration have more antibacterial activity, comparing to lower 
concentrations [155][149].  
Also peptide orientation after immobilization on the surface may influence its 
antibacterial activity. Peptides can be immobilized by different chain positions, namely C-
terminal and N-terminal. The orientation of the peptide may determine the way it can 
interact with bacteria, namely with lipid bilayer during membrane pore formation [119][153].  
During this work two different AMPs (CM and MSI-78) and two different strategies to 
immobilize them (surface covalent immobilization and bulk physical incorporation) will be 
explored.  
 
2.4.3 Cecropin-Melittin (CM) 
 
An hybrid of cecropin and melittin (Figure 16), is a combined AMP very efficient against 
gram-positive and gram-negative bacteria [156].  
Cecropin peptides are composed of 35 to 39 amino acids in the form of two α-helix 
structures linked by a flexible segment and in a amphipathic form [157]. These peptides 
integrate a class of AMPs generated at the humoral immune system in insects (they can also 
be obtained from pigs). Cecropins have the ability to interact with membrane lipids to form 
channels with increased antimicrobial activity [158]. Also, they can inhibit protein 
importation and control or even inhibit mitochondrial respiration when in higher
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 concentrations. These peptides have the advantage of not causing lyses in eukaryotic cells 
(non toxic) [159].  
Melittin is a amphipatic AMP of 26 amino acids organized in a α-helix structure. It is 
commonly found in the venom of honey bee [160]. In spite of its antimicrobial activity, at 
high concentrations, this peptide causes lyses in red blood cells, being toxic to the organism. 
In addition, displays antiviral activity even at lower concentrations, being capable of 
disrupting viral membranes [161], [162]. 
Cecropin and melittin conjugation allow a more efficient defense mechanism to be 
formed. The segments of cecropin combined with melittin, increase antimicrobial activity, 
comparing to cecropin alone [163]. Also the association of this two AMPs decrease the 
hemolytic activity of melittin, becoming non toxic to the organism [164], [165]. Together, 
these two peptides are capable of exerting a broad antimicrobial activity against not only 
bacteria but also fungi, virus and protozoa [166], [167].  
This hybrid chemical structure can be seen in Figure 14.  
 
 
 
Figure 16- Chemical structure of CM [168]. 
 
2.4.4  Pexiganan (MSI-78) 
  
MSI-78 is an AMP with 22 amino-acid sequence (GIGKFLKKAKKFGKAFVKILKK) (Figure 17) 
and   an analog of the natural AMP, magainin 2, that can be isolated from the skin of Xenopus 
laevis, an African frog [169]. This synthetic peptide was developed to treat foot ulcers [170] 
A great problem associated with magainin, is the loss of activity in animal models of 
infection, leading to the use of high doses of peptide that can become toxic to the organism. 
This way, new synthetic AMPs have been developed, with increased activity to overcome this 
problem [171] .  
MSI-78  makes part of the α- helical group of AMPs and presents a broad spectrum of 
antibacterial activity against gram-positive and gram-negative bacteria. This antimicrobial 
activity is due to the ability of MSI-78 to disrupt bacterial membranes by forming toroidal 
pores (toroidal pore model) [172][173].  
Studies were made, in order to improve MSI-78 activity or stability, by creating derivates 
of MSI-78 with similar structure but with different characteristics. In one of those studies, 
realized by our team, MSI-78 shorter derivates were designed to improve bacterial selectivity 
while maintaining antimicrobial activity and therefore, decrease the high cost of production 
associated with peptide synthesis [4].
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In this work, two MSI-78 derivated AMPs were used, MSI-78 (1-17) and MSI-78 (2-18). Those 
AMPs presents 17 amino acids sequence, GIGKFLKKAKKFGKAFV for MSI-78 (1-17) and 
IGKFLKKAKKFGKAFVK for MSI-78 (2-18).  
 
 
Figure 17- Chemical structure of Pexiganan [174]. 
 
Chapter 3 
Surface Characterization Techniques 
Several characterization techniques were used to analyze the surface of the materials 
studied in this work: PU, Au NPs and CM. The convergence of different characterization 
techniques allowed us to evaluate each surface from different angles: visual aspect, 
roughness, wettability and elemental composition. 
 
3.1 Scanning Electron Microscopy (SEM)   
 
SEM analyses the samples with a focused electron beam and deliver images with 
information about sample’s topography and composition (Figure 18). This technique uses a 
high energy beam of electrons in a raster scan pattern that interacts with the atoms on the 
surface, under vacuum conditions. Those electrons carry high amounts of kinetic energy that 
is dissipated as a variety of signals produced by electron-sample interactions when the 
incident electrons are decelerated in the solid sample. These signals include secondary 
electrons, backscattered electrons, diffracted backscattered electrons, photons, visible light, 
and heat.  
The signals that derive from electron-sample interactions are detected and contain 
information about the sample's morphology and topography, chemical composition and 
crystalline structure. Secondary electrons are most valuable for showing morphology and 
topography on samples, and that was the main information we wanted to obtain about our 
samples, using SEM [175][14].
30 
 
 
(A)                                                                 (B) 
Figure 18- SEM equipment (A) and schematic representation of its components (B) (adapted from [176]). 
 
3.2 Contact Angle Measurements 
  
Contact angle measurements provide information about the surface wettability and its 
free energy. The contact angle is the angle, usually measured through the liquid, where a 
liquid–vapor interface encounters the solid surface (Figure 19). The contact angle 
measurement is based on the balance between the force of attraction of the liquid molecules 
to each other, and the attraction of the liquid molecules to the molecules of the surface. 
When a drop of liquid is placed on the surface, it spreads to reach equilibrium between 
cohesive (of attraction of the liquid molecules to each other) and adhesive (attraction of the 
liquid molecules to the molecules of the surface) forces with minimum energy.  
There are several methods to determine a contact angle between a liquid and a surface, 
but one of the most common methods is the sessile drop (applied in this work). This is one of 
the most simple techniques in which a drop of a liquid (in this case water) is placed with a 
syringe on the surface and a video camera captures the image allowing the software to 
determine the contact angle between the drop and the surface with time, by recurring to 
mathematic functions as Young- Laplace [177]. 
A contact angle inferior to 90° indicates that the liquid spreads over a large area of the 
surface (wetting the surface), while a contact angle superior to 90° indicates that the liquid 
minimizes the contact with the surface (unfavorable for wetting the surface) [178]. This way, 
providing information about the nature of the surface, hydrophobic or hydrophilic (Figure 3).  
 
 
      (A)                                                                          (B) 
Figure 19- Contact angle measurement equipment (A). Contact angle observed in a hydrophobic and a 
hydrophilic surface (B) (adapted from [179]).
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3.3 Ellipsometry 
 
Ellipsometry is an optical technique that measures changes in the state of polarization of 
the light upon reflection from a surface. If the surface was coated with an ultrathin film 
(<100 nm) this technique can measure the thickness of the film through the alteration on the 
state of polarization of the light in comparison with the same measure on the surface without 
coating.. A plane-polarized laser beam, emitted by a source light is usually reflected from the 
coated surface and its polarization analyzed with a compensator/detector couple (Figure 20). 
This change in polarization state depends on the film thickness, the refractive index, which is 
a measure of the bending of a ray of light when passing from one medium into another, and 
the extinction coefficient that is a measure of the rate of diminution of transmitted light via 
scattering and absorption for a medium [180].  
 
     
 
(A)                                                               (B) 
Figure 20- Ellipsometer equipment (A). Schematic representation of the ellipsometer setup (B) [181]. 
 
3.4 X-ray Photoelectron Spectroscopy (XPS) 
 
XPS is a spectroscopic technique based on the photoelectric effect, a phenomena that 
happens when a material is exposed to electromagnetic radiation emitting an electron. 
This technique measures the elemental composition in a surface. XPS measures the 
kinetic energy and the number of inner shell photoelectrons that escape from the material 
surface  irradiated with mono-energetic x-rays beam in ultra high vacuum (Figure 21).  
The energy of the emitted core level electrons is measured and its value provides 
information about the nature and environment of the atom from which it came, according to 
the equation below: 
 
BE= hν – KE                                                                     (1.1) 
 
Where, 
BE is the energy binding the electron to an atom (value we want to know)  
KE is the kinetic energy of the emitted electron (value measured) 
 hν is the energy of the X-rays, a known value. 
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There is an energy characteristic for every chemical element that can be used to 
determine the elemental composition of a sample. The photoelectrons are detected by a 
electron detector and its energy is measured by an electrostatic analyzer. By analyzing the 
energy and intensity of the photoelectron peaks is possible to obtain several information 
about the identity, chemical state and quantity of each element present [14]. The ultra high 
vacuum chamber is also an important component since it keep a sterile environment assuring 
the absence of other elements during the analysis, and, consequently, assumes that all the 
detected elements belong to the sample in analysis [18].  
 
(A)                                                                   (B) 
Figure 21- XPS equipment (A). Schematic representation of XPS components in detail (B), adapted from 
[182]. 
 
3.5 Attenuated Total Reflection - Fourier-Transform InfraRed 
Spectroscopy (ATR-FTIR) 
 
ATR-FTIR is a chemical imaging technique to identify and quantify functional groups in 
molecules.  Here, a sample is crossed by infrared radiation being part of the radiation 
absorbed by the sample and the other part transmitted. The resultant spectrum represents 
the molecular absorption and transmission characteristic of each sample analyzed. It also 
works as a fingerprint of the sample with absorption peaks that represent the frequencies of 
vibration between the bonds of the atoms [183].  
There are different sample handling techniques in FTIR, however, the one used in this 
work was ATR. The method applied depends mainly on the nature of the sample, and in ATR-
FTIR spectroscopy an attenuated total reflection accessory operates by measuring the 
changes that occur in a totally internally reflected infrared beam when the beam comes into 
contact with a sample (Figure 22)  [184].
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(A)                                                            (B) 
Figure 22- ATR-FTIR equipment (A). Schematic representation of sample analysis with ATR-FTIR 
spectroscopy (B) (adapted from [185]). 
 
3.6 Quartz Crystal Microbalance with Dissipation (QCM-D) 
 
QCM-D is an equipment that uses a simple and efficient technique based on the 
piezoelectric effect (Figure 23). Piezoelectricity is the capacity of some crystals to generate 
an electrical tension in response to a mechanical pressure. Quartz is one of the materials with 
this capacity, and gathering with other particularities, makes it perfect for QCM-D 
applications. Indeed, it is possible to excite the crystal and make it oscillate by applying an 
AC potential difference between the two electrodes. Therefore, with this equipment it is 
possible to evaluate mass variation per area unit by measuring frequency changes of a quartz 
crystal resonator. 
 The sensor that measures these variations is composed of the quartz crystal placed 
between two electrodes that can apply an alternating voltage on the sensor causing it to 
oscillate at a specific frequency. The frequency of oscillation depends on the thickness of the 
crystal; thus, a mass alteration on the surface of the crystal will lead to a frequency change: 
for example, when a mass is deposited on the quartz crystal the thickness increases, 
provoking a decrease in the oscillation frequency. The total mass oscillating includes the 
adherent material on the surface and the water coupled to the material [186].  
This relationship between frequency changes and mass alteration  is explained by the 
Sauerbrey equation:  
 
                                (1.2) 
Where, 
   is the observed frequency change in Hz 
   is the change in mass per unit area in g/cm2 
  is the sensitivity factor for the crystal (17.7 ng/s.cm2). 
For the Sauerbrey relationship to work it needs to respect some assumptions, (1) the 
adsorbed mass must be much smaller than the mass of the quartz crystal, and (2) should be 
evenly distributed on the crystal surface. Besides, the deposited mass should not affect the 
vibration mode of the crystal, which is only valid for rigid layers as those do not display 
vibrational frequency; this relation can only be applied to rigid adherent masses. 
Some QCM-D are also equipped with dissipation factor monitoring, QCM-D. The dissipation 
factor relates to the viscoelastic properties of the sample and is measured simultaneously 
with the frequency to help the analysis.
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 QCM-D has a wide range of applications in different fields of investigation as biomaterials, 
environment, cellular and molecular biology, biofuels, among others. This equipment, allows 
a real-time analysis of surface phenomena as film formation, molecular adsorption or 
interactions on various surfaces. It can be used to evaluate protein adsorption, cell 
attachment, biomineralizaton, polyelectrolyte multilayers, hemocompatibility, etc. One of 
the main applications of QCM-D is in the analysis and investigation of biomaterials [187]. In 
this work, we used QCM-D to evaluate the stability of films/coatings and quantify protein 
adsorption related to hemocompatibility.  
There are several types of QCM-D but the model used in this work was the Q-Sense E4 by 
Bioloin Scientific. This model presents 4 channels for quartz crystals, allowing a rapid and 
efficient analysis of molecular interactions in four different crystals.  
The electrodes are placed into a chamber specifically designed for controlled flow 
measurements and constant temperature. The liquid injection or extraction and its flow rate 
are controlled by a pump external to this chamber and that can be controlled by the 
operator. The crystals used in this equipment can be prepared with different coatings like 
gold, silicon dioxide, stainless steel, titanium, etc., according to the objective of the 
measurement [187]. 
 
        (A)                                                                    (B)  
Figure 23- QCM-D equipment (A). Schematic representation of a QCM-D crystal and sensing principle (B) 
(adapted from [188]).  
 
 
 Chapter 4 
Materials and Methods 
4.1 Surfaces Preparation 
 
PU films were prepared by casting (4.1.2.1) and PU ultrathin coatings deposited on top of 
gold substrates and gold sensors, were produced by spin coating. The use of gold surfaces 
allowed the application of characterization techniques like ellipsometry and QCM-D. In Figure 
24 it is possible to see the different sort of samples used: a PU film, a gold substrate and a 
gold sensor.  
 
 
Figure 24- Gold substrate and sensor on which PU ultra thin films were produced and PU film produced 
by casting. 
 
4.1.1. Polyetherurethane (PU) 
 
PU, Pellethane 2363 80 AE (Figure 25), was commercially obtained in the form of pellets 
from Dow Chemical. Pellets were cleaned twice with hexane and once with ethanol (15 min 
sonication) to eliminate any trace of silicone used during the pellets processing. This process 
was repeated twice. After, PU pellets were dried overnight in a vacuum oven at room 
temperature (RT).                                                                  . 
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Figure 25- Pellethane chemical structure. Adapted from [189]. 
 
4.1.2 PU Processing 
 
4.1.2.1. PU Films Casting 
  
PU films were prepared as previously described [190]. PU was dissolved at 12.5% in 
tetrahydrofuran (THF, Sigma) and 40 mL of the solution were casted onto clean glass petri 
dishes of 140 mm of diameter. THF was left to evaporate overnight and, then, thin films were 
cut in small disks of 13 mm of diameter and washed 3 times with ddH2O (water type 2) (5 min 
sonication) to remove possible impurities from the cutting process. After, 2/3 of the PU films 
were sent to Matera, a company located at Biocant Park in Cantenhede for CM immobilization 
and the other 1/3 was used as control.  
 
4.1.2.2. PU Ultrathin Coatings (Spin Coating) 
 
PU solution at 0.1% was prepared by dissolving PU pellets in THF. Drops of 80 µL were 
dispensed on the center of gold surfaces (substrates or sensors cleaned according to the 
described below) strategically positioned in the spin coater equipment. Its process of work 
can be observed in Figure 26.  Surfaces were spun at 9000 rpm for 1 min. PU coated surfaces 
were then left to dry in a vacuum oven at RT for 1 h. After, 2/3 of the PU coated surfaces 
were sent to Matera, at Biocant Park in Cantenhede for CM immobilization and the other 1/3 
was used as control. 
 
 
Figure 26- Spin coating working principle.
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a) Gold Substrates for Ellipsometry (Cleaning Process)   
 
Gold coated silicon wafers, of 1 x 1 cm2 (Figure 27) were obtained from INESC 
Microsystems & Nanotechnologies (INESC-MN) and prepared as previously described by our 
group [191]. To prevent contamination during dicing, storage and transport, gold substrates 
were coated with a 1.2 μm layer of positive photoresist (reference PFR7790, from JSR) soluble 
in acetone.  
Prior to use, gold substrates were washed to remove both the photoresist and possible 
organic residues. First, gold substrates were immersed in 10 mL of acetone (99.5% Merck 
Millipore) and sonicated for 3 min using polypropylene (PP) flasks. This step was repeated 
twice. Then, they were rinsed with absolute ethanol (99.9% Merck Millipore) to eliminate all 
traces of acetone and were immersed in “piranha” solution (7 parts concentrated sulfuric 
acid and 3 parts hydrogen peroxide (at 30% vol., VWR) for 5 min (Note: this solution reacts 
violently with many organic materials, namely with acetone, and should be handled with 
care)[78].  Gold substrates were afterwards transfer to new PP flasks, immersed in absolute 
ethanol and sonicated for another 3 min. This step was repeated once more using Milli-Q 
water (type 1). At the end, gold substrates were rinsed with ethanol and dried with a gentle 
argon stream. 
 
 
Figure 27- Gold coated silicon wafer where gold subtracts were extracted from. 
 
b) Gold Sensors for QCM-D (Cleaning Process) 
 
Gold coated sensors, with fundamental resonance of 5 MHz, were purchased from Q-Sense 
(Biolin Scientific) and used as received. For consecutive testing, pre-used sensors were 
washed as follows: first, sensors were oxidized in an ultra violet (UV) oven for 10 min; then 
immersed for 5 min in a solution containing: 10 mL of water type 1 with 2 mL ammonia 
(Merck, 25%) and 2 mL hydrogen peroxide solution (30% vol.) heated at 75ºC. Finally, sensors 
were rinsed and sonicated for 3 min in water type 1. O-rings from the QCM-D system were 
sonicated with 2% Hellmanex for 3 min, rinsed and sonicated twice for 3 min in water type 1. 
In the end, both sensors and O-rings were dried with argon stream and stored at RT in an
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 oxygen free environment. In Figure 28, it is possible to see the flow module of QCM-D with 
the O-ring and gold sensor. 
 
 
Figure 28- Flow module of a QCM-D with an O-ring and a gold sensor. 
 
4.1.3 CM Immobilization onto PU 
4.1.3.1. Au NPs Synthesis and Immobilization onto PU Surfaces 
 
Au NPs were synthesized by the Turkevich's method [192]. Briefly, 90 mL of 10-4 M 
Chloroauric Acid (HAuCl4) solution were mixed with 10 mL of a solution containing 0.2mg 
sodium citrate (Sigma) and left boiling until the color of the solution changed from light 
yellow to ruby-red.  
Polyurethane films were cleaned with 20% ethanol aqueous solution and subsequently with 
water type 1. After, PU films were immersed in Silicon tetrachloride (SiCl4) in anhydrous 
toluene solution (5%) for 5 min, washed with ethanol to remove excess SiCl4 and were left at 
RT for 24 h, to allow hydrolysis to occur, creating free hydroxyl groups on PU surface. Then, 
PU films were immersed in 1% (v/v) 3-amino propyltrimethoxysilane (APTMS) prepared in an 
ethanolic solution (4%(v/v)) ethanol in water type 1 with pH ~4.5 adjusted with acetic acid) 
for 30 min and washed with ethanol. Then, APTMS treated films were incubated in the 
solution of Au NPs for 24 h. At the end, PU-Au NPs were washed twice with water type 2 and 
dried with argon. Au NPs coated surfaces were used as control in characterization techniques. 
 
4.1.3.2 Covalent Immobilization of CM onto PU Surfaces 
 
CM peptide with a cysteine at the C terminal (KWKLFKKIGAVLKVLC) was purchased from 
Caslo Laboratory, Denmark with 98% purity. CM immobilization onto PU was conducted as 
previously described [118]. In few words, PU-Au NPs were functionalized with polyethylene 
glycol (PEG)-spacers, HS-PEG-NH2 and HS-PEG-COOH (1:1 molar ratio) (1 kDa, 0.9 mM, 1 
mg/mL) for 24 h. Unbound molecules were removed by rinsing with water type 1. Then, 
surfaces were incubated in N-[γ-maleimidobutyryloxy]sulfosuccinimide ester solution (sulfo-
GMBS, 1 mg/mL in 100 mM phosphate buffer at pH 7.2) for 2 h to modify the amine groups 
and expose maleimide groups that will bind to HS-groups of CM (obtained by the introduction 
of a cysteine residue at C-terminal). Activated surfaces were then immersed into CM peptide
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 solution (1-3 mg/mL in phosphate buffer (pH 7.2)) for covalent immobilization, during 24 h at 
4ºC. Unbound peptide was removed by rinsing with phosphate buffer.  
The amount of peptide immobilized was estimated using the sulfosuccinimidyl-4-o-(4,4-
dimethoxytrityl)butyrate (sulfo-SDTB) test according to manufacturer instructions [118], 
[153].A schematic representation of  immobilization process can be observed in Figure 29 (A), 
and is possible to see in the final step we obtain a zwitterionic surface. A zwitterionic surface 
has positively and negatively charged groups, and in this case, the surface will have positive 
charge from the CM peptide and negative charge from the COOH group.   
 
 
(A) 
 
(B) 
  
                 (C) 
Figure 29- Schematic representation of the PU surfaces modification with Au NPs and CM (A). Final 
scheme of CM immobilization on PU (B). PU films before (PU) and after surface modification (PU-Au NPs 
and PU-Au NPs-CM) (B).
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4.1.4 Physical Incorporation of MSI-78-derived Peptides into PU Films 
 
MSI-78 derived peptides, MSI-78 (1-17) and MSI-78 (2-18), were incorporated in PU films 
during casting. MSI-78 peptides were prepared at 32, 64 and 128 µg/mL in 25 mL of THF. 
Vancomicin (Sigma), an antibiotic, was prepared at 64 µg/mL in 25 mL of THF and used as a 
second control. After peptide dissolution, PU pellets, treated as described in section 4.1.1, 
were added to the peptide solution. Once the PU pellets were completely dissolved, the 25 
mL of solution were casted onto clean glass petri dishes of 80 mm of diameter. THF was left 
to evaporate overnight. The produced films were cut in small disks of 13 mm of diameter, 
inside a flow chamber to prevent contamination. 
 
 
4.2 Surface Characterization 
 
4.2.1 Scanning Electron Microscopy (SEM) 
 
Surface micrographies of PU, PU-Au NPs and PU-Au NPs-CM films were taken using a high 
resolution SEM with X-ray Microanalysis, JEOL JSM 6301F/Oxford INCA Energy 350 at CEMUP 
(Centro de Materiais da Universidade do Porto). An electron beam intensity of 5 kV 
(accelerating voltage) was used and images were taken at 2,000x and 200,000x magnification. 
To increase the surfaces conductivity, the films were sputtered with Au/Pd for 60 seconds 
and 15 mA current using the SPI Module Sputter Coater equipment.  
Platelet adhesion was examined with beam intensity at 10 kV and magnifications of 
2,000x and 4,000x. Again, surfaces were pre-coated with Au/Pd for 60 seconds at a 15 mA 
current.  
 
4.2.2 Water Contact Angle Determination 
 
Water contact angle measurements were performed using a Data Physics, Model OCA 15, 
equipped with video CCD-camera. Samples (PU, PU-Au NPs and PU-Au NPs-CM) were placed in 
a closed thermostated chamber (25ºC) saturated with water type 2 to prevent droplet 
evaporation. 4 µL water type 2 droplets (syringe) were placed on the surface of each film and 
the angle measured using the sessile drop method. Angle variations with time were recorded 
during 3 min, 30 times per second using the SCA 20 software. Droplet profiles were fitted 
using the Young-Laplace mathematical function. The contact angle respective to each film 
was calculated by extrapolating the time-dependent curve to zero [193]. 3 replicates of each 
(PU, PU-Au NPs and PU-Au NPs-CM) were analyzed. 
 
4.2.3 Ellipsometry  
 
Ellipsometry measurements were performed using an ellipsometer from Nanofilm Surface 
Analysis, model EP3. The light source was a laser of wavelength of 532 nm. The gold sample 
refractive index (n) and extinction coefficient (k) were determined by using delta and psi
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 spectrum with variation of angle between 66°and 76°. The measurements were made in four 
zones to confirm a correct alignment, on 3 samples. To determine the thickness of PU, the n 
and k of the gold substrates were set as 0.6647 and 2.6112 respectively [194], and the final 
angle used was 71º. Assays were performed using 3 replicates of each sample (PU and PU-Au 
NPs). 
 
 
4.2.4 X-ray Photoelectron Spectroscopy (XPS) 
 
XPS measurements were conducted using a VG Scientific ESCALAB 200A (UK) spectrometer 
with an AlKα X-ray source of 1486.6 eV, operating at 15 kV (300W) to estimate photoemission 
(CEMUP). Photoelectrons were analyzed at a 55º takeoff angle and at 100 Å of the outermost 
layer. Survey scans were acquired with a pass energy of 50 eV. High-resolution spectra of 
carbon (C), nitrogen (N), oxygen (O), sulfur (S), silicon (Si) and gold (Au) were collected with 
analyzer energy of 20 eV. These were resolved into individual Gaussian peaks using the 
XPSPEAK 4.1 software and fitted by setting the maximum of the resolved C(1s) peak, 
correspondent to C in a hydrocarbon environment (CHx), to 285.0 eV. 
 
4.2.5 Fourier Transformed Infrared – Attenuated Total Reflectance (ATR- 
FTIR) 
 
ATR- FTIR measurements were performed with a Perkin Elmer FTIR spectrophotometer, 
model 2000. To realize the measurements an ATR accessory (SplitPea) was used. This 
accessory is configured to apply localized, measured pressure to produce superior contact 
between the sample and the ATR crystal, so the PU films were gently pressed against the 
crystal during readings. Infrared spectra for each sample were obtained by performing 100 
scans with a resolution of 4 cm-1. 
 
 
4.3 QCM-D Testing  
 
4.3.1 Stability of Au NPs and CM Coating 
 
The stability of the Au NPs and CM coatings on PU was tested by QCM-D. Sterile phosphate 
buffered saline solution (PBS) at pH=7.4 was continuously injected into the QCM-D system 
with gradually increasing flow rates, that changed every hour: 12.5, 25, 50, 75, 100, 150 and 
200 µL/min. Tests lasted 7 hours. Au NPS and CM-coated sensors were tested after 
immobilization in two different types of PU: PU unmodified (P_U) and PU chemically 
activated with SiCl4 (PU_ChA). This allows us to understand if PU treatment influences Au NPs 
and CM immobilization and consequently their stability on its surface. Results were reported 
both in frequency variation (Δf) and mass (ng/cm2), according to Sauerbrey equation 
explained in section 3.6.                                                                       .
42 
 
4.3.2 Adsorption of Blood Plasma 
 
Adsorption of proteins from blood plasma on the differently treated QCM-D sensors was 
monitor in real time using the QCM-D system. PBS was used as baseline and left for ≈ 10 min 
in contact with the sensors. 1% human plasma (provided by Centro Hospitalar de São João, 
HSJ, Porto) in PBS was then added and left to adsorb until saturation (up to 3 h). The entire 
experiment was conducted at 37ºC and 25 µL/min. Data are reported as frequency variation 
(Δf) and mass (ng/cm2), according to Sauerbrey equation explained in section 3.6. 
After each protein adsorption tests, the modules composing the QCM–D system were 
cleaned. Each module was flushed with 2% Hellmanex in ddH2O for 10 min at 400 µL/min (to 
remove the protein layer from both sensors and modules) and water type 1 for another 20 min 
at equal flow rate. To clean the QCM system, sensors and O-rings were substituted by others 
sensors and O-rings that are only used for cleaning the system and each module was flushed 
with 2% Hellmanex (10 min) and water type 1  (20 min) at 400 µL/min. 
Finally, the cleaning sensors and O-rings were removed and the modules were dried with 
compressed air.  
 
4.4 Platelets Adhesion and Activation 
 
Samples were sterilized by their immersion in 70% ethanol (Valente e Ribeiro, Lda.) for 15 
min. This step was repeated and after, surfaces were dried with argon in sterile environment.  
Sterilized samples were then pre-immersed in PBS or 1% human plasma (in PBS) for 30 
minutes at 37ºC and then washed 3 times with PBS. Simultaneously, 24-well tissue culture 
polystyrene (TCPS) plates (Sarstedt) were blocked with 1% bovine serum albumin (BSA) in PBS 
for 1 hour at 37ºC, under static conditions. TCPS plates were then washed five times with 
PBS. Films were then incubated with freshly prepared platelet solution at 3x108 platelets/mL 
in PBS for 30 minutes at 37ºC (70 rpm) on the BSA-blocked TCPS plates. After incubation, 
samples were washed three times with PBS. Adhered platelets were fixated with 1.5% 
glutaraldehyde (Merck) in 0.14 M sodium cacodylate (Merck) buffer for 30 min at RT and then 
rinsed twice with water type 2. After, the films were dehydrated in a growing ethanol/water 
gradient, 50%-99% followed by critical point drying. The amount of adhered platelets and its 
degree of activation was followed by SEM by counting the number of platelets on 5 images 
collected at different sections of each film. Results were reported as number of 
platelets/mm2 or percentage per degree of activation. A scale of platelet degree of activation 
can be observed below in Figure 30. 
  
Figure 30 - SEM images illustrating the five types of platelet shapes, from less activated to the most 
activated state. round or discoid (R); dendritic or early pseudopodial (D); spread-dendritic or 
intermediate pseudopodial (SD); spread or late pseudopodial (S)   and fully spread (FS). Scheme 
produced with original images based on [54].                                                                              .
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4.5 Antimicrobial and Anti-Adhesive Properties of CM Coatings 
 
4.5.1. Bacteria Strains and Growth Conditions 
 
Staphylococus epidermidis (ATCC 35984), clinical isolated from an infected catheter and 
high slime producer, was obtained from the American Type Culture Collection. Bacteria were 
grown in trypticase soy agar (TSA, Merck) plates overnight at 37ºC (bacteria spreading) and 
trypticase soy broth (TSB, Merck) overnight at 37ºC and 150 rpm (bacteria inoculum). 
 
4.5.2. Bacterial Adhesion 
 
Surfaces were sterilized with ethanol 70% for 30 min in 24-well TCPS plates and then 
washed 3 times with PBS. After, surfaces were dried with argon in sterile environment.  Films 
were incubated in PBS or 1% human plasma (in PBS) for 30 min at 37ºC. After washing 3 times 
with PBS samples were incubated in 1 mL of bacteria solution with 1x107 Colony-Forming 
Units (CFUs) /mL in PBS for 2 h at 37ºC. After adhesion, bacteria solution was removed and 
the samples were washed 3 times with PBS. Bacteria adhered to the surfaces were fixated 
with 4% paraformaldehyde in PBS for 20 min at RT. After, surfaces were washed 3 times with 
PBS, mounted in slides and stained with VECTASHIELD
 
Mounting Medium with 4’,6- diamidino-
2-phenylindole (DAPI; Vector). Samples were stored at -20ºC protected from the light until 
observation in the inverted fluorescence microscope (Axiovert 200 M, Zeiss, Germany). The 
number of bacteria/mm2 was determined by counting the number of bacteria found in ten 
fields of 0.01 mm2, per sample, using the ImageJ software. 
 
4.5.3. Bacteria Viability 
 
Viability of adherent bacteria was assessed using the LIVE/DEAD® Bacterial Viability Kit 
(BaclightTM). Surfaces were challenged with bacteria as described in 4.5.2. After incubation 
with the bacterial suspension, surfaces were washed twice with PBS and once with 0.85% 
Sodium Chloride (NaCL). Then, surfaces were stained with a combination of two dyes, red-
fluorescent propidium iodide (excited at 535 nm) and green-fluorescent syto 9 (excited at 485 
nm) for 15 min at RT, protected from light, according to manufacturer instructions. 
Propidium iodide (red) labels only dead bacteria, since it only penetrate damaged 
membranes, whereas syto 9 (green) labels nucleic acids of both live and dead bacteria. 
Finally, surfaces were mounted in slides using VECTASHIELD
 
with DAPI for microscopy 
observation. Images were obtained with an inverted florescence microscope. The number of 
bacteria/mm2 was determined by counting the number of bacteria found in ten fields of 0.01 
mm2, per sample, using the ImageJ software. 
 
4.6 Antimicrobial Activity of PU Films Containing MSI-78 (1-17) 
and MSI-78 (2-18)  
 
 Antimicrobial activity of the PU films containing AMPs was evaluated by a bacterial 
adhesion assay modified from Pallavicini et al [195]. Surfaces were placed in a 24-well TCPS 
plate and a drop of 10 µL of bacterial suspension adjusted to 1x107 CFUs/mL, in PBS or 1%
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 human plasma, was placed on top of each sample. Subsequently, the bacterial suspension 
was covered by a sterilized glass coverslip (VWR) of equal diameter, facilitating contact 
between the microorganisms and the surface. After 5 h incubation at 37ºC in wet 
environment, 1 mL of PBS was added to each well. Films were re-suspended until detachment 
of the coverslip was observed. After that, the coverslip was removed and a series of dilutions 
from 100 to 10-5 of the supernatant were done to count the number of CFUs. For that, three 
drops of 10 µL each per dilution factor were plated in TSA containing Petri dishes and placed 
in an incubator overnight at 37ºC.   
 
4.7  Statistical Analysis 
 
Statistical analysis was performed using ANOVA or Paired t-test. Data is expressed as the 
mean ± standard deviation (SD) and p values <0.05 were considered significant, with * 
corresponding to p<0.05, **corresponding to p< 0.01, *** corresponding to p<0.001 and **** 
corresponding to p<0.0001. 
 
 
 
Chapter 5 
Results and Discussion 
5.1 Surfaces Characterization 
  
5.1.1 Stability of Coatings 
To evaluate the stability of the Au NPs and CM coatings on PU, a QCM-D test was 
performed using PU-coated QCM gold sensors under injection of PBS (37ºC) at increasing 
velocities, from 12.5 to 200 µL/min, for 7 hours. With this assay, it is expected to evaluate 
the importance of the chemical activation of PU film, before Au NPs immobilization, on the 
resistance of the coatings under flow conditions and predict their stability in a dynamic 
cardiovascular system. QCM-D translates alterations on the frequency of vibration of the 
quartz crystal into mass changes. The increase of its frequency of vibration is translated into 
mass loss, while its decrease is translated into mass gain. Moreover, higher frequency 
variation indicates higher mass changes.  
Figure 31 A and B show the frequency of vibration profiles registered on PU-Au NPs and 
PU-Au NPs-CM, respectively. Stability tests were conducted using PU that was firstly 
chemically activated with SiCl4 (as explained in section 4.1.3.1) (chemically activated PU; 
PU_ChA) before Au NP and CM immobilization, and PU that was not pre-activated (unmodified 
PU; PU_U).  
Results showed an increase of the frequency of vibration of sensors coated with PU-Au NPs 
and PU-Au NPs-CM, if PU surfaces were not chemically activated (PU_U). These alterations 
were visible after 300 min, when the flow rate was changed from 75 to 100 µL/min.  In 
opposite, when PU was chemically activated (PU_ChA), the immobilization process was stable 
in the entire assay. The increase of the PU-Au NPs (PU_U) frequency (~20 Hz) can be related 
with the removal of gold nanoparticles (very small particles). The increase in the PU-Au NPs-
CM frequency (200 Hz) can be related to the removal of gold nanoparticles bound to CM. This
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 higher frequency shift suggests that the immobilized CM or even the immobilization process 
facilitates the release of the coating if PU was not activated.  
 
 
(A)                                                                      (B) 
 
(C) 
Figure 31- (A) PU-Au NPs and Pu-Au NPs-CM (B) stability profiles from 7 h injection of PBS at different 
speeds (from 12.5 to 200 µL/min) in PU_ChA and PU_U . (C) Total mass changes registered on the 
surfaces in PU_ChA and PU_U. Positive values correspond to mass loss and negative values correspond to 
mass accumulation, on the sensor. Statistically significant differences are indicated with * (p<0.05, 
ANOVA). 
Concerning PU_ChA, the small increase of the frequency (~3 Hz) could be related with 
release of very few Au NPs. In contrast, the very small decrease in the PU-Au NPs-CM on 
PU_ChA can probably be explained by the adsorption of some salts from the buffer (PBS) at 
37°C. Still, in both cases the variations are too small to be considered, in view of the Au NPs 
and CM molecular weights of 16548 kDa and 1874 kDa, respectively. Figure 31 C, which 
translates these shifts in frequency of vibration into mass changes using the Sauberbrey 
equation, shows exactly this. The mass variation is clearly very small, less than 100 ng/cm2, 
for the chemically modified surfaces (PU_ChA) and much higher for the unmodified (PU_U) 
~2800 ng/cm2 (p<0.05, ANOVA). The results show the need of chemically treating the PU 
surface prior to the immobilization of both the Au NPs and the CM in order to acquire stable 
and functional coatings.  This step made part of optimization of the immobilization process in
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 PU and, after understand that without the PU pre-activation step the immobilization process 
was compromised, PU was always pre-activated according to previously described [196].  
 
5.1.2 Scanning Electron Microscopy (SEM) 
 
Figure 32 shows the evident differences in surface morphology of PU, PU-Au NPs and PU-
Au NPs-CM, obtained by SEM.  
The PU coating exhibits a smooth morphology/topography. The addition of nanoparticles 
increased the roughness of the surface. Moreover, at higher magnification the distribution of 
Au NPs can be observed. The expected size of the Au NPs was 14 nm, however, as we can see 
in Figure 32, the obtained value for Au NPs size was around 25 nm, suggesting some particles 
aggregation. After CM immobilization, it is possible to distinguish the nanoparticles, smaller 
in size (~18 nm) and more defined than on PU-AU NPs, which could be explained by the high 
affinity of the thiol group of the PEG-spacer to gold that could dissolve/remove some Au NPs 
aggregates [197]. Moreover, Au NPs immobilization was followed by 3 steps of chemical 
reactions and washing procedures, which can facilitate the dissolution of Au NPs aggregates.    
 
 
Figure 32- Surface morphology of PU, PU-Au NPs and PU-Au NPs-CM obtained by SEM at 2,000x and 
200,000xmagnification.
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5.1.3 Water Contact Angle 
 
In order to evaluate the wettability of the different surfaces, water contact angle 
measurements were conducted (Figure 33). PU showed a water contact angle of 80°, similar 
with previously reported [190]. Au NPs immobilization did not significantly change the water 
contact angle (82°), which can be related with the increase of surface roughness and the 
introduction of CH3/CH2 groups from APMTS. However, CM immobilization decreased the 
water contact angle (67°) of the surface in a significant way (p<0.05, ANOVA). This increase 
of surface hydrophilicity can be related not only to CM immobilization but also to the thiol-
PEG-NH2 and thiol-PEG-COOH that was firstly immobilized onto Au NPs. This results are also 
consistent with previous published work[96].  
 
  (A) 
 
   (B) 
Figure 33- (A) Water optical contact angles of the surfaces PU, PU-Au NPs and PU-Au NPs-CM. (B) 
Appearance of water drop in contact with the each surface. Statistically significant differences are 
indicated with * (p<0.05, ANOVA). 
 
5.1.4 Thickness of Coatings: Ellipsometry 
 
Ellipsometry was used to determine the thickness of the film after each immobilization 
process, since it is expected to detect an increase in the film thickness if immobilization 
occurs.  
As explained in section 3.3, ellipsometry measures changes in the state of polarization of 
the light upon reflection from a surface. This technique can measure film thickness up to 100 
nm. It was not possible to measure the thickness of the films after CM immobilization, due to 
dispersion of the light suggesting that film could have a thickness near 100nm. This way, 
thickness measurements were only performed on PU and PU-Au NPs surfaces.  
Figure 34 A shows the average thickness of PU and PU-Au NPs surfaces. It was observed, 
that after Au NPs treatment the film thickness increased ~23 nm (p<0.001, t-test). This value
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 is similar to the size of the nanoparticles (~20-25 nm), so this result confirms Au NPs 
immobilization on PU, with the increase on the thickness being caused by nanoparticles 
addition. 
 Figure 34 B shows the similarity between the images of gold substrates coated with PU 
and PU-Au NPs, displayed during thickness measurements. PU-Au NPs presents some small 
particles that could be related with the surface immobilization process.  
 
 
 (A) 
 
(B) 
Figure 34 – (A) Results from ellipsometry on PU and PU-Au NPs. Statistically significant differences are 
indicated with *** (p<0.001). (B) Aspect of the surfaces during ellipsometry assay. 
 
5.1.5 X-ray Photoelectron Spectroscopy (XPS) 
 
Atomic composition of the surfaces, PU, PU-Au NPs and PU-Au NPs-CM, determined using 
XPS is described in Table 2. The elements analyzed were Carbon (C), Nitrogen (N), Oxygen 
(O), Sulfur (S), Silicon (Si) and Gold (Au). Results demonstrated that no elements other than 
those expected were found, indicating that no contamination took place.  
The atomic composition of the PU revealed a high percentage of Carbon and Oxygen and a 
lower % of Nitrogen, as previously described [198] [190].  
After coating with Au NPs, surface presented silicon and gold, as expected from PU 
coating with SiCL4, APTMS (3-amino propyltrimethoxysilane) and from the Gold nanoparticles 
respectively (Table 2). In Table 3, it is possible to see the different Carbon e Sulfur bonds 
obtained by high-resolution XPS spectra. After Au NPs addition there is an increase of C1s 
with binding energies at 285 eV and 288 eV. The peak at 285 eV can be assigned to CH2/CH3
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 groups and the peak at 288 eV to -O-C-O-, both present in APTMS. In addition, the decrease 
of carbon at 285.6 eV (C-O-C) from the PU composition also indicates that the PU was covered 
with other compounds, namely APTMS and Au NPs. 
After spacer (HS-PEG-NH2 and HS-PEG-COOH) and cysteine-CM (HS-CM) immobilization, 
there is the appearance of Sulfur and an increase of Nitrogen and Carbon (Table 2). These 
elements are part of the spacer and peptide composition and their increase demonstrate the 
success of the spacer and CM immobilization. In addition, there was a decrease on Gold 
relative percentage after CM immobilization and Silicon was not detected. This could be 
related with Silicon deeper location.  Table 3 shows the increase of carbon at 286 eV, 
assigned to a Carbon bond to one Oxygen, indicating the presence of PEG -(CH2-CH2-O)n- and, 
the increase of carbon at 288 eV, which is associated with the presence of the spacer (COOH-
PEG) and the peptide (-N-C=O;  from the peptide bond). In addition, the presence of S2p at 
162 eV indicates thiol-PEG-spacers bonded to Au NPs (S-Au) and S2p at 164 eV can be related 
to the thioether group (S-C) formed by the link between the HS-CM and the maleimide group 
(from the sulfo-GMBS). These results can confirm the success of CM covalent immobilization.  
 
Table 2- Surface atomic composition (%) of the different samples calculated from high-
resolution XPS spectra. 
 
 
 
Table 3- Surface composition (%) of Carbon and Sulfur calculated from high-resolution XPS 
spectra. 
 
% C1s % S2p 
BE (eV)  285.0 286.5 288.0 162.0 164.0 
 
C-C; C-H 
C-NH2; C-OH; 
C-O-C 
O-C-O; 
N-C=O 
S-Au S-C 
PU 63 35 2 0 0 
PU-Au NPs 71 24 5 0 0 
PU-Au NPs-CM 52 41 7 34 66 
 
Atomic Percentage (%) 
 
C1s N1s O1s S2p Si2p Au4f 
PU 79 3 18 0 0 0 
PU-Au NPs 59 2 17 0 14 7 
PU-Au NPs-CM 71 6 16 1 0 6 
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5.1.6 Fourier Transformed Infrared – Attenuated Total Reflectance (ATR- 
FTIR) 
 
To evaluate eventual modification in chemical bonds on the different surfaces, with 
peptide addition, ATR-FTIR was performed (Figure 35).  
FTIR spectra of PU films demonstrated PU characteristic absorption bands, namely the 
absorption bands at 1595 cm-1 and 1413 cm-1 from benzene ring and at 1528 cm-1 from N-H 
and C-N from the urethane group [199] [190]. After nanoparticles and peptide addition it was 
expected to observe some modification on the characteristic absorption bands of the 
proteins/peptides:  Amide I (C=O) at 1690 cm-1 and Amide II (C-N) at 1540 cm-1. However, 
such changes were not detected [200].  
Since Au NPS and CM immobilization was no detected by this technique but was detected 
by others (such as XPS and spectroscopy), we believe that surface immobilization occurred at 
a very superficial layer in the PU film. This can be explained since this technique has a depth 
of penetration in the order of micrometers [184], and the Au NPs and CM layers are in the 
order of nanometers. This way, the equipment detect a big amount of the bulk (PU), losing 
some sensitivity for more superficial layers (Au NPs and CM), causing PU-Au NPs and PU-Au 
NPs-CM surfaces to present the same spectra as PU. 
 
 
Figure 35- FTIR-ATR spectra of PU, PU-Au NPs and PU-Au NPs-CM. 
 
5.1.7 Immobilized CM quantification 
 
Results from spectroscopy analysis demonstrated that CM was successfully immobilized on 
Au NPs-coated surfaces in a concentration of 68 g/cm2. 
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5.2 Biological Testing 
 
5.2.1 Protein Adsorption 
 
Using QCM-D, the adsorption of human plasma proteins on PU, Au NPs and CM coated 
surfaces was investigated using human plasma at 1% in PBS and a flow rate of 25 µL/min 
(37ºC).  
Figure 36 (A,B,C) shows the protein adsorption profiles on the three surfaces. It was 
observed that plasma proteins rapidly adsorbs to all the surfaces tested. In all the samples 
there is a decrease on the frequency of sensor vibration until a plateau was reached.  On PU 
samples, the frequency decreased up to around 60 Hz, on PU-Au NPs until approximately 52 
Hz and on CM coated surfaces until 38 Hz. The time to reach the plateau (saturation), 
moment in which there are no more active sites on the surface for protein binding, was 
different between surfaces. For instance, PU, which experienced a superior frequency shift, 
took less time to reach saturation than the PU-Au NPs and especially the PU-Au NPs-CM 
surfaces, which frequency shift was smaller.  
Differences on the kinetics of protein adsorption are related with the type of surface, 
namely its wettability and if they have affinity to certain proteins that adsorbs faster, 
particularly albumin. This protein is always the first protein to contact with surfaces due to 
its higher concentration in plasma (40mg/mL) and their small size (MW=66kDa) and higher 
diffusion coefficient (DC) (6.1x10-7 cm2/s). However, depending of the surface, adsorbed 
albumin can be exchanged by other plasma proteins that exist in lower concentration and are 
usually larger in size (immunoglobulins with concentrations ~15mg/mL; MW=150kDa and 
DC=4x10-7 cm2/s; fibrinogen with concentrations ~3mg/mL; MW=340 kDa and DC= 2x10-7 
cm2/s, etc) [49]. This process is known as Vroman effect [3].  However, QCM-D can only 
distinguish the type of adsorbed protein using specific antibodies against each suspected 
adsorbed protein, which could be a complicated and expensive process [201]. In general, 
hydrophobic surfaces adsorb more proteins in a faster and irreversibly way. 
Figure 36 D shows the total amount of protein adsorbed on the three surfaces.  The amount of 
plasma proteins adsorbed on PU and Au NPs was similar and higher than on CM-coated PU 
(p<0.0001, ANOVA). This could be related with their similar and higher hydrophobicity (water 
contact angle ~80º). It has been shown that the hydrophobic character of surfaces increases 
the adsorption of proteins since hydrophobic surfaces allow interaction with hydrophobic 
domains and residues in the protein [202].  
The lower protein adsorption on CM-coated PU is a quite positive outcome, as some adsorbed 
proteins may induce bacterial adhesion, coagulation/complement activation and platelet 
adhesion/activation. This lower protein adsorption on CM-coated PU can be related with i) 
surface immobilization of a non-fouling polymer (PEG-spacer) and/or ii) creation of a 
zwitterionic surface (surface with negative and positive charged groups) that was obtained by 
the combination of COOH-PEG spacer with a cationic peptide (CM rich in arginine amino acids: 
KWKLFKKIGAVLKVLC). This antifouling ability of hydrophilic and zwitterionic surfaces is 
correlated with a hydration layer near the surface. This tightly bound water layer forms a 
physical and energetic barrier to prevent protein adsorption on the surface. Removal of water 
molecules from the surface, is the first and obligatory step to facilitate protein adsorption by
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 reducing free energy barrier arising from dehydration entropic effects. If the water layer 
cannot be removed protein adsorption will be limited [203] [204]. 
           (A)                                                     (B) 
 
(C) (D)  
Figure 36- (A,B,C) QCM-D protein adsorption profiles from 1% human plasma in PBS on PU, Au NPs and 
CM. (D)Total amount of proteins adsorbed from 1% human plasma in PBS on PU, Au NPs and CM. 
Statistically significant differences are indicated with **** (p<0.0001). 
 
5.2.2 Platelet Adhesion and Activation 
 
Figure 37 demonstrated that CM coating (PU-Au NPs-CM) significantly decrease platelet 
adhesion to PU, independently of the media used, PBS (p<0.001, ANOVA) or 1% human plasma 
(p<0.05, ANOVA). This result suggests that CM coating may provide anti-adhesive properties to 
the surface, possibly due to its hydrophilic characteristics and low protein adsorption. These 
results are consistent with a work previously published, in which more hydrophobic surfaces 
presented a higher number of adhered platelets, comparing to more hydrophilic surfaces [54]. 
Pre-immersion in human plasma slightly increased the number of adhered platelets to CM-
coated PU comparing to pre-immersion in PBS, although these differences are not statistically 
significant (Figure 37). Although it was demonstrated that PU surface adsorbs more plasma 
proteins than PU-Au NPs-CM (Figure 36), pre-adsorption in human plasma did not affect 
platelet adhesion to PU. This could be explained by the elevated number of platelets that 
were able to adherent to the hydrophobic PU surface in PBS.  
Concerning platelet activation, Figure 38 shows that CM immobilization did not induce 
platelet activation in comparison with PU surface independently of the presence (Figure 38B)
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 of pre-adsorbed plasma proteins (1% human plasma) (Figure 38A). This results are quite 
positive since it is not only important to decrease platelet adhesion to the catheters surface 
but also to avoid its activation because activated platelet are more likely to induce thrombus 
formation. In addition, it was also demonstrated that adsorbed plasma proteins decrease 
platelet activation in both surfaces, suggesting that the adsorbed protein layer is not 
composed with fibrinogen, vitronectin or von Willebrand factor, the proteins that, after 
adsorption to a surface, are responsible for platelet adhesion/activation [54]. These are very 
promising results since intravascular catheters will be always in direct contact with blood and 
therefore in contact with plasma proteins.  
Representative images of platelets adhesion and activation in contact with each surface 
can be observed in Figure 39. 
 
 
Figure 37 - Adhesion of human platelets on PU, PU-Au NPs and PU-Au NPs-CM. Surfaces were pre-
immersed in PBS or 1% human plasma. Statistically significant differences are indicated with * (p<0.05) 
and *** (p<0.001). 
 
(A)         (B) 
Figure 38 - Platelet shape distribution on PU, PU-Au NPs and PU-Au NPs-CM.  Surfaces were pre 
immersed in PBS (A) or 1% human plasma (B).
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Figure 39- Representative images of platelets adhesion and activation in contact with PU and PU-Au NP-
CM surfaces in the presence of PBS and 1% human plasma.  Images were obtained by SEM at 2,000x 
magnification. 
 
5.2.3. Bacterial Adhesion to CM coating 
 
Bacteria adhesion assays demonstrated that CM immobilization decreases bacteria 
adhesion to PU when surface are pre-immersed in PBS (p<0.05, ANOVA) (Figure 40). These 
results suggest that CM immobilization provide anti-adhesive properties to PU, as verified on 
platelets assays. This anti-adhesive property of CM-coated PU may be related to its more 
hydrophilic character as explained before. However, in the presence of plasma proteins, 
there are no significant differences among PU and PU-Au NPs-CM surfaces. The decrease on 
bacteria adhesion to PU after plasma incubation, suggests that the adsorbed protein layer is 
mostly composed by albumin known as an anti-bacterial adhesion agent [205]. However, since 
this albumin “passivant” effect was not observed on platelet adhesion (Figure 37), more 
assays must be conducted to clarify the composition of the adsorbed protein layer, namely 
the type and conformation of adsorbed proteins.   
Representative images can be observed in Figure 41.
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Figure 40- Total number of adherent bacteria on PU, PU-Au NPS and PU-Au NPs-CM. Statistically 
significant differences are indicated with **** (p<0.0001). 
 
Figure 41- Representative images of bacteria adhesion to PU and PU-Au NP-CM surfaces in the presence 
of PBS and 1% human plasma.  Images were obtained by MIF at 100x with oil, 20 µm scale.
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5.2.4. Viability of adherent bacteria 
 
Concerning bacteria viability, Figure 42 shows that all bacteria adherent to CM-coated PU 
are dead, contrary to PU surfaces where more than 50% of adherent bacteria are alive. These 
results are consistet with a previous work where the high antimicrobial activity of CM was 
verified, although immobilized in a different surface [206].  
The presence of plasma proteins did not compromise the antibacterial effect of CM, since 
the number of dead bacteria is similar to the number of total adhered bacteria, suggesting 
that this surface is able to kill adherent bacteria by contact, even in the presence of human 
plasma. These results are quite promising since our CM coating seems to have not anti-
adhesive properties but also antimicrobial activity. This way, it may be able to decrease 
bacterial adhesion to catheters and also to kill the few bacteria that still can adhere to the 
device. 
 
   
 
 
Figure 42- Comparison between total and dead adhered bacteria. 
 
 
5.3 MSI-78 (1-17) and MSI-78 (2-18) Antimicrobial Activity 
 
5.3.1. Antimicrobial activity assay 
 
Antimicrobial activity of PU films containing MSI-78-derived peptides, Figure 43 
demonstrated that both peptides, MSI-78 (1-17) and MSI-78 (2-18), are able to kill S. 
epidermidis in a concentration dependent way. The antibiotic used as a second control, 
vancomycin, presented some antibacterial activity comparing to the main control, PU. 
However, PU films with AMPs presented higher antibacterial activity than PU with 
vancomycin.  
When efficacy assays were performed in PBS, the decrease in CFUs due to the 
incorporation of AMPs on PU was statically significant (p<0.05, ANOVA) for MSI-78 (1-17) with 
concentration 64 and 128 µg/mL and for MSI-78 (2-18) with all concentrations tested (Figure 
42 A). However, when efficacy studies were performed with bacteria suspended in human 
plasma, the antimicrobial effect of both peptides decrease although there are still
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 statistically significant differences for MSI-78 (1-17) with 128 µg/mL concentration and for 
MSI-78 (2-18) with all concentration used.  
 
 
 
(A)                                                                                      (B) 
Figure 43- Number of CFUs after contact with the surfaces (bacteria solution in PBS) (A). Number of 
CFUs after contact with the surfaces (bacteria solution in 1% human plasma) (B). Statistically significant 
differences, comparing to the control (PU), are indicated with ** (p<0.01), *** (p<0.001), **** (p<0.0001). 
Statistically significant differences, comparing to lower peptide concentrations (32 µg/mL) are 
indicated with ‘a’. 
 
Between different concentrations of the same peptide there was no statistic difference for 
MSI-78 (1-17) neither for MSI-78 (2-18).  
The results suggests that both PU-MSI-78 (1-17) and PU-MSI-78 (2-18) have antibacterial 
activity, however, while PU-MSI-78 (1-17) only demonstrates activity in high concentrations 
(64 and 128 µg/mL in PBS and 128 µg/mL in 1% human plasma), MSI-78 (2-18) presents activity 
even in low concentration (32 µg/mL) both in PBS and 1% human plasma presence. These 
results are different from expected, since in solution MSI-78 (1-17) presented a higher 
antimicrobial activity against S. epidermidis (Minimal Inhibitory Concentration- MIC =4-8 
µg/mL) comparing to MSI-78 (2-18) (MIC=16-32 µg/mL) [4]. The differences in our results 
could be related with different peptides release profile from the PU. It could be possible that 
although very similar in composition, with only one different aminoacid (GIGKFLKKAKKFGKAFV 
for MSI-78 (1-17) and IGKFLKKAKKFGKAFVK for MSI-78 (2-18)), MSI-78 (2-18) releases more 
easily from the PU comparing to MSI-78 (1-17).  
To evaluate MSI-78 release kinetics from PU, both peptides will be synthesized with a 
fluorescent label to follow its release, both in PBS and in human plasma, to clarify if the 
differences on their antimicrobial properties can become from different release 
characteristics.  
 
 
Chapter 6 
Conclusions and Future Perspectives 
The aim of this research work was the development of PU coatings with antimicrobial 
activity against bacteria, namely S. epidermidis without inducing thrombus formation, namely 
platelet adhesion and activation. 
During the first part of the work, the AMP cecropin-melittin (CM) was successfully 
covalently immobilized onto PU films, using several chemical sequential steps that goes 
briefly from the activation of PU films, the binding of gold nanoparticles (Au NPs) and finally 
the CM coupling. Since PU was not easy to modify chemically, its pre-activation with SiCl4 
was essential for the stability of the coating in flow conditions as demonstrated by us, using 
QCM-D. Surface characterization techniques also proved that CM was successfully 
immobilized. SEM showed an increase of the roughness of PU due to the presence of Au NPs 
and CM immobilization. Au NPs with ~25nm can be observed using this technique, however 
with CM addition, the nanoparticles seem a bit smaller ~20 nm. Surface wettability was also 
modified after peptide immobilization, with a decrease of the water contact angle on the 
surface, proving once more the peptide presence. Ellipsometry showed an increase in surface 
thickness with AU NPs immobilization proving their presence, however, this technique did not 
allow us to see the thickness increase with CM immobilization, probably due to the high 
thickness increase with CM addition, exceeding the equipment analysis capacity (100nm). XPS 
results were also consistent with other characterization techniques, showing an increase on 
Au percentage with Au NPs immobilization. After peptide addition, an increase on the relative 
atomic percentage of Sulphur, Nitrogen and Carbon was observed. This was expected since 
these elements are part of peptide composition (Nitrogen and Carbon from all amino acids 
and Sulfur from the cysteine).  Moreover, Sulphur can also be from the spacer used (thiol-
PEG) in immobilization process, and its increase suggests spacer and CM efficient
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 immobilization.  ATR-FTIR was also performed on the samples, but no differences were 
observed between them. However, the depth of analysis of this technique is in the order of 
micrometers, decreasing its sensitivity for alterations on the first surface layers of the 
samples. These results suggest that this immobilization process occurred on the first surface 
layers of PU films.   
It was also demonstrated that CM coating decreased the kinetic and the amount of plasma 
proteins adsorption on PU. These results are quite positive since avoiding protein adsorption 
on the surface could prevent future bacteria or platelets adhesion and activation. Tests with 
total blood would be enriching for this study. Moreover, it will be very important to evaluate 
which plasma proteins adsorb preferentially on CM coating, namely albumin, fibrinogen and 
other proteins involved in contact and complement activation. 
CM-coated surfaces also showed a decrease in platelets adhesion, possibly because the 
higher hydrophilicity of these surfaces compared to PU. In the presence of plasma proteins, 
this tendency was maintained although the number of adherent platelets on CM-surface has 
duplicated. Nevertheless, adherent platelets in the presence of plasma proteins are in a 
lower state of activation suggesting that adsorbed plasma proteins may avoid platelet 
activation and thus prevent thrombus formation. However, more studies need to be done in 
the future to completely evaluate the hemocompatibility of this CM-coating, namely 
coagulation and complement activation and leukocyte adhesion and activation. 
Antibacterial efficacy studies showed a decrease on S. epidermidis adhesion to CM-coated 
surface, proving that this surface have anti-adhesive properties. Viability tests proved that 
bacteria adherent to CM-coated surfaces are dead, suggesting that immobilized CM can kill 
bacteria by contact even in the presence of plasma proteins In the future, it would be 
important to evaluate the mechanism of action of the immobilized CM namely if after killing 
by contact, namely if bacteria membrane was destroyed and if dead bacteria were released 
from the surface. Moreover, biofilm formation was not tested during this work, but the 
understanding of the effect of the immobilized CM on biofilm production is essential. Off 
course that in the future it would be also very important to test other bacteria involved in 
catheter-related infections. 
During the second part of this research work, the MSI-78 (1-17) and MSI-78 (2-18) peptides 
were incorporated on PU films and their bactericidal effect was also evaluated using S. 
epidermidis. This part of the work is still in a very initial phase, so surface characterization 
and AMP delivery were not performed yet. However, some promising results were already 
achieved. 
Antimicrobial activity assays, showed that the peptides even in low concentrations (32 
µg/mL) are able to kill bacteria after contact with the surface both in 1% human plasma 
presence and absence. This effect was superior for a higher peptide concentration. Both PU 
films showed good results, however, PU with MSI-78 (2-18) has higher antimicrobial activity.
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 This was not expected, since in solution, MSI-78 (1-17) has a lower MIC than MSI-78 (2-18) to 
this bacterium, suggesting that MSI-78 (2-18) could have a faster release from the PU film.  
As said before, these results are very positive, suggesting that incorporation of AMPs on PU 
may be a promising, simple and innovative way to produce materials with antimicrobial 
activity. However, more studies need to be performed in the future. It is important to 
characterize the surfaces, namely the alteration of their mechanical properties with increase 
of AMP concentration and their stability in physiological conditions and their 
hemocompatibility. Moreover, it will be necessary to evaluate the kinetic of peptide delivery 
from the surface that can be easily realized using fluorescent labeled AMPs. 
As concluding remarks it is possible to say that this research work achieved most of its 
main goal, obtaining surfaces for blood contact with antimicrobial properties without inducing 
platelet adhesion and activation. However, although results were very promising, more 
studies need to be done in the future to evaluate their application as intravascular catheters 
coating. 
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